

1 **Functional MRS studies of GABA and Glutamate/Glx – a systematic review and meta-analysis**

2 Duanghathai Pasanta^{1,2}, Jason L. He¹, Talitha Ford^{3,4}, Georg Oeltzschnner^{5,6}, David J. Lythgoe⁷, Nicolaas A.
3 Puts^{1,8}

4 ¹. Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and
5 Neuroscience, King's College London, London, London SE5 8AB, United Kingdom

6 ². Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University,
7 Chiang Mai, 50200, Thailand

8 ³. Cognitive Neuroscience Unit, School of Psychology, Deakin University, Locked Bag 20000, Geelong,
9 Victoria 3220, Australia

10 ⁴. Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria,
11 Australia

12 ⁵. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, 700. N. Broadway,
13 21207, Baltimore, United States

14 ⁶. Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School
15 of Medicine, 601 N. Wolfe Street, 21205, Baltimore, United States

16 ⁷. Department of Neuroimaging, Institute of Psychiatry, Psychology, and Neuroscience, King's College
17 London, London, London SE5 8AB, United Kingdom

18 ⁸. MRC Centre for Neurodevelopmental Disorders, New Hunt's House, Guy's Campus, King's College
19 London, London SE1 1UL, London, United Kingdom

20

21 **Corresponding author email address:**

22 nicolaas.puts@kcl.ac.uk

23 Number of pages:

24 Number of figures, tables, multimedia, and 3D models (separately): 11 figures, 1 table

25 Number of words for abstract, introduction, and discussion (separately): Abstract 212 words, Introduction
26 1391 words, Discussion 4702 words

27 Conflict of interest statement: The authors declare no competing financial interests.

28 Acknowledgments: DP is funded by a Chang Phueak Scholarship, Chiang Mai University, ChiangMai,
29 Thailand. GO receives salary support from R00 AG062230 and R21 EB033516.

30 **Abstract**

31 Functional magnetic resonance spectroscopy (fMRS) can be used to investigate neurometabolic
32 responses to external stimuli in-vivo, but findings are inconsistent. We performed a systematic
33 review and meta-analysis on fMRS studies of the primary neurotransmitters Glutamate (Glu), Glx
34 (Glutamate + Glutamine), and GABA. Data were extracted, grouped by metabolite, stimulus
35 domain, and brain region, and analysed by determining standardized effect sizes. The quality of
36 individual studies was rated. When results were analysed by metabolite type small to moderate
37 effect sizes of 0.29-0.47 ($p < 0.05$) were observed for changes in Glu and Glx regardless of
38 stimulus domain and brain region, but no significant effects were observed for GABA. Further
39 analysis suggests that Glu, Glx and GABA responses differ by stimulus domain or task and vary
40 depending on the time course of stimulation and data acquisition. Here, we establish effect sizes
41 and directionality of GABA, Glu and Glx response in fMRS. This work highlights the importance of
42 standardised reporting and minimal best practice for fMRS research.

43

44

45

46

47

48

49 **Introduction**

50 **1. Background**

51 γ -aminobutyric acid (GABA) and glutamate (Glu), the main inhibitory and excitatory
52 neurotransmitters in the brain, respectively, are critical for normal neurological function. GABA
53 and Glu play an important role in perception (Edden et al., 2009; Puts et al., 2011), learning (Floyer-
54 Lea et al., 2006), memory (Jo et al., 2014), and other behavioural functions (Paredes and Agmo,
55 1992; Donahue et al., 2010). GABA and Glu are known to interact, due to the fact that GABA is
56 synthesized by using glutamic acid decarboxylase (GAD) by removing an α -carboxyl group from
57 Glu (Cai et al., 2012). Several lines of evidence suggest that an imbalance in GABAergic and
58 glutamatergic function is associated with neurological, neurodevelopmental, and neuropsychiatric
59 disorders (Li et al., 2019; Tang et al., 2021; Nakahara et al., 2022). The interplay of GABA and Glu
60 is of strong interest due to their role in excitatory and inhibitory (E/I balance) which was theorised
61 to play important part in healthy brain function and that the disruption of E/I balance is shared by
62 several psychiatric disorders (Yizhar et al., 2011; Ferguson and Gao, 2018).

63 In humans, Magnetic Resonance Spectroscopy (MRS) is the only technique that allows for
64 the non-invasive *in vivo* measurement of wide range of neurometabolites including GABA and Glu
65 (Mullins et al., 2014; Schür et al., 2016; Harris et al., 2017). MRS allows for the quantification of
66 endogenous brain metabolites based on their chemical structure. ^1H -proton containing
67 metabolites each have their own distinct chemical environment and thus appear differently along
68 a “chemical shift” axis, although with substantial overlap. Recent developments in MRS
69 instrumental and acquisition technique have broadened our knowledge of brain neurochemistry

70 in both clinical and research domains, and this has been extensively reviewed (Duarte et al., 2012;
71 Faghihi et al., 2017).

72 While baseline GABA and Glu levels have been associated with typical and atypical brain
73 function and behaviour (Coghlan et al., 2012; Horder et al., 2018), metabolite levels assessed at
74 rest limit interpretation; as they cannot provide information on the temporal dynamics of GABA
75 and Glu, which may provide insight into typical or atypical function, the relationship between
76 GABA and Glu, task-related changes, and responses to pharmacological intervention. This has led
77 to an increased interest in functional MRS studies, which have the potential to measure a dynamic
78 neurochemical system.

79 1.1 Functional MRS

80 Functional MRS (fMRS) refers to the use of MRS to estimate metabolite *changes* in
81 response to external stimulation by acquiring data at different time point associated with changes
82 in stimulus presentation. Typically, MRS spectra result from an averaged signal from repeated
83 measurements (transients) to improve signal to noise ratio (SNR) as metabolites have an
84 inherently low SNR due to their low concentration. A single transient refers to the data collected
85 in each repeat (repetition time, TR) during the MRS acquisition. The often-used term 'averages' in
86 MRS stems from the averaging of these transients for a single 'average' spectrum. Functional MRS
87 uses the same approach but tend to measure the signal in shorter durations, or average a smaller
88 set of transients, than in static MRS. In this study, we refer to the number of repeated acquisitions
89 per time point as transients to avoid confusion with the act of spectral averaging. It should be
90 noted that different acquisition sequences exist for MRS, with the most popular single-voxel MRS
91 sequences being spin-echo point-resolved spectroscopy (PRESS) (Bottomley, 1987), stimulated
92 echo acquisition mode (STEAM) (Frahm et al., 1989), semi localization by adiabatic selective
93 refocusing (sLASER)(Öz and Tkáč, 2011), and spin-echo full intensity acquired localised (SPECIAL)
94 (Kuwabara et al., 1995). Details on these approaches are beyond the scope of this work but details
95 can be found in recent consensus work (Peek et al., 2020; Lin et al., 2021).

96 fMRS has been used to study wide range of brain chemistry, includes high-concentration
97 metabolites, such as N-acetyl aspartate, creatine, and choline, to low-concentration metabolites

98 such as lactate (see (Prichard, 1992; Chen et al., 1993; Henning, 2018; Wilson et al., 2019; Peek et
99 al., 2020)). While the fMRS of Glu, and particularly that of GABA is of immense interest due to their
100 critical role in brain function, fMRS of these other metabolites is not yet well-established due to
101 technical considerations (e.g., an absence of lactate at baseline) and perhaps more difficult
102 interpretation of its outcomes).

103 Glu and GABA overlap considerably with signals from glutamine (Gln) and glutathione
104 (GSH), particularly at clinical field strength (3 T) (see 1.4). Still, despite these challenges, fMRS of
105 GABA and Glu has been used to study neurochemical changes associated with various type of
106 exogenous change, including pain (Gutzeit et al., 2013; Cleve et al., 2015), visual stimulation
107 (Mangia et al., 2007; Apšvalka et al., 2015; Bednářík et al., 2015), working memory (Woodcock et
108 al., 2018), learning and memory (Stanley et al., 2017), and motor tasks (Schaller et al., 2014;
109 Kolasinski et al., 2019). However, substantial inconsistencies between studies exist in terms of
110 acquisition, analysis, findings, and interpretation. To date, the body of fMRS literature on Glu and
111 GABA has not been systematically evaluated and analysed. From hereon we refer to fMRS studies
112 of GABA and Glu as 'fMRS'.

113 1.2 Limitations in estimating GABA and Glu

114 The measurement of GABA and Glu is challenging and contributes to variability across
115 studies. GABA has a low concentration within the brain (1 - 2 mM), and its signal overlaps with
116 high-concentration metabolites like NAA and creatine, as well as very similar chemical shift
117 between Glu, Gln, and GSH. Spectral-editing techniques such as MEscher-Garwood Point-RESolved
118 SpectroScopy (MEGA-PRESS) are often used to improve GABA resolution (Mescher et al., 1998;
119 Edden and Barker, 2007; Near et al., 2011). These approaches rely on J-difference editing of the
120 GABA signal, removing unwanted signal from the spectrum. For a technical review, see (Puts and
121 Edden, 2012; Mullins et al., 2014; Wilson et al., 2019; Deelchand et al., 2021). Spectral-editing
122 MRS techniques typically requires more transients (in the order of 8 minutes; 240+ transients for
123 voxel sizes of 27 ml based on consensus for adequate data acquisition at 3T) compared to non-
124 edited sequences for Glu (64 transients for voxel sizes of 8 ml at 3T) (Peek et al., 2020; Lin et al.,
125 2021). Differences in MRS sequences, especially editing sequences, may affect the ability to

126 interpret and reproduce studies (Terpstra et al., 2016; Baeshen et al., 2020). Whether linear-
127 combination modelling approaches can successfully and reliably separate Glu from Gln, GABA and
128 GSH remains inconclusive (Sanaei Nezhad et al., 2018; Zöllner et al., 2021) and thus, the composite
129 measure Glx (= Glu + Gln) is commonly reported.

130

131 **1.3 Heterogeneity in fMRS approaches**

132 There is little homogeneity regarding fMRS experimental design, stimulus type, brain region and
133 the quality of MRS acquisition and analysis methods — all of which often depends on the research
134 question. fMRS can typically be performed using two types of experimental paradigms, block-
135 designs or event-related designs (Mullins, 2018). Block designs contrast metabolite measurements
136 between acquisition blocks that are often long in duration and contain numerous stimuli and
137 transients. Event-related approaches rely on time-locking stimulus onset with the MRS acquisition
138 and allow for the investigation of transient metabolite levels changes immediately after stimulus
139 onset (stimulus-locked). Block approaches typically have more SNR as more transients are
140 averaged across per spectrum and from the summation of responses presented in close
141 succession but have limited interpretability of stimulus-locked neurochemical responses. Effect
142 sizes are heterogeneous, with reported observed effect sizes (*if at all* reported) range from 2% to
143 18% change from baseline for visual stimulation, and up to 18% change from baseline for painful
144 stimulation (Gussew et al., 2010; Mullins, 2018; Stanley and Raz, 2018). Event-related designs are
145 more tightly associated with stimulus timings, but often suffer from low SNR due to a limited
146 number of transients being averaged across. Both approaches are limited by multiple unknowns
147 such as: the response function describing the delay between stimulus and neurotransmitter
148 change, optimal acquisition duration and timing, and optimal data analysis techniques.

149 **1.4. Our approach**

150 One prior meta-analysis of fMRS studies focused exclusively on Glu (Mullins, 2018),
151 however, no meta-analysis it yet to investigate the fMRS of GABA. With increasing interest in GABA
152 and the popular concept of excitation-inhibition balance (E/I), a comprehensive meta-analysis of
153 both GABA and Glu is of strong interest. We then further investigate potential factors that could

154 affect outcomes in fMRS studies including fMRS design, fMRS parameters, quality of MRS studies
155 and other source of bias.

156

157 **2. Materials and Methods**

158 **2.1 Search strategy and Inclusion criteria**

159 A systematic search of databases (Pubmed, Ovid Medline, and Google Scholar) was
160 performed using a search Boolean generated from *litsrchr* package in R (Grames et al., 2019)
161 combined with additional search terms based on discussion with co-author NAP (For search terms,
162 see Supplementary Table 1). After the initial search on 21st May 2021, the abstract of each article
163 was screened to identify relevant studies using the *metagear* package in R (Lajeunesse, 2016). The
164 studies that met the following criteria were included: 1) use of in- vivo fMRS to measure
165 neurometabolites in the brain; 2) the study investigated changes in GABA or Glutamate (both Glu
166 and Glx) in response to non-invasive stimuli or tasks; 3) the study participants were healthy adult
167 humans or the study contained a healthy human control group (no psychiatric or neurological
168 condition); 4) the study had a baseline or control condition; 5) the study was published in a peer-
169 reviewed journal, and was written in English or translated to English via Google Translate. Relevant
170 articles from the reference sections of included studies were identified and manually added to the
171 analysis after being discussed with a senior author (NAP).

172

173 **2.2 Study selection and data extraction**

174 Following PRISMA and PROSPERO guidelines for systematic evidence synthesis, we pre-
175 registered this meta-analysis on Prospero (CRD42021257339) and identified relevant literature
176 (Tricco et al., 2018). A two-stage method was used for study selection (Furlan et al., 2009). In the
177 first stage, potentially relevant titles and abstracts were independently assessed by two
178 investigators (DP and NAP). If the abstract was inconclusive, the full text was retrieved and
179 assessed for eligibility. In the second stage, the investigators independently assessed the full text

180 of potential studies selected in the first stage for their eligibility. A third investigator (JH) was
181 consulted if disagreements persisted in both stages. Reasons for exclusion were documented.

182 Two investigators (DP and NAP) independently extracted the data using an identical extraction
183 sheet. Data were extracted into four main topics of interest: 1) neurometabolite levels during
184 fMRS; 2) study characteristics (i.e., sample size, age, gender); 3) reported MRS acquisition
185 parameters according to the MRS-Q (e.g., MRS sequence, fMRS paradigm and timing, voxel size,
186 TE, TR, pre- and post-processing); and 4) bibliometric data (e.g., authors, year of publication, and
187 type of publication).

188 Concentrations of GABA, Glu and Glx were taken as reported by the study, mean and
189 standard deviation (SD; mean_{metab}) or as percentage change from baseline (%change_{metab}). While
190 it is possible to perform a meta-analysis on *all* data calculated as %change_{metab}, the SD of these
191 two types of data are on different scales and therefore should not be combined together (Higgins,
192 2011). Our approach allows data points to be combined while avoiding secondary calculation of
193 data. The data, whether time point or time-course data, were considered as separate datapoints
194 and compared to 'rest' or 'baseline', as long as the actual data are reported separately.
195 Dependence of time-course data is discussed below in section 2.5. If numerical data were not
196 explicitly reported, imputation methods recommended by the Cochrane handbook were used
197 (Higgins et al., 2011). Data not reported in-text but in figures were extracted using
198 WebPlotDigitizer (Rohatgi, 2021). The time from the start of the MRS acquisition to the time of
199 metabolite measurement was also extracted. Differences between brain regions (voxels) were
200 considered independent and therefore data from multiple brain regions acquired in a single study
201 were extracted as independent datapoints (Peek et al., 2020). If limited studies of specific voxels
202 were available, we grouped them based on a broader brain region (e.g., 'frontal', or 'parietal').

203

204 2.3 Quality assessment

205 The Risk of Bias Assessment tool for Non-randomized Studies (ROBANS) (Kim et al., 2013a)
206 was used to determine the quality of the methodological design and reporting. MRS-Q (Peek et
207 al., 2020) and <https://osf.io/8s7j9/>, is a quality appraisal tool specifically designed for the

208 systematic review of MRS studies. The MRS-Q was used to assess whether the reported acquisition
209 methods satisfy the minimal best practice in MRS. The MRS-Q allows for assessing both the
210 acquisition approach and whether reporting was adequate (Peek et al., 2020), and is in line with
211 the recently published MRSinMRS (Lin et al., 2021). As the MRS-Q was designed for static MRS, its
212 application for functional MRS experiments is discussed further in the *Discussion*). Studies were
213 categorised into “low-quality” and “high-quality” based on the adequacy of reported MRS
214 parameters. Studies that reported sufficient spectroscopy parameters and satisfy the consensus
215 for adequate data acquisition were classified as ‘high quality’, studies that reported insufficient
216 spectroscopy parameters or did not satisfy the consensus for adequate data acquisition were
217 classified as ‘low quality’, and studies with not enough information to classify were considered
218 ‘unsure’. While we used these terms (as per these guidelines) these do not always reflect that the
219 study itself of low quality but perhaps did not report sufficient information per recommendation.
220 We should also consider these in the context of history. As detailed below, we analyse data with
221 and without inclusion of “low-quality” papers, but also perform a more dimensional approach,
222 testing the association between effect size and acquisition parameters. Two investigators (DP and
223 NAP) independently assessed the quality of each study using both tools. Disagreements were
224 discussed and resolved by consensus with a third investigator (JH).

225

226 2.4 Publication bias

227 Data were assessed for publication bias separately for each metabolite (GABA and Glu/Glx).
228 The effect sizes were then aggregated for each metabolite within each study to avoid non-
229 independence effects using Egger’s regression and trim-and-fill test (Duval and Tweedie, 2000;
230 Bowden et al., 2015; Nakagawa et al., 2021). For the trim-and-fill test, a random-effects model
231 was used on aggregated data, thus not accounting for non-independent effect sizes. Then, the
232 Knapp and Hartung method (IntHout et al., 2014) was used to test for publication bias instead of
233 the Wald test (Z-tests) as it has been suggested to have better performance on trim-and-fill
234 approaches (Nakagawa et al., 2021).

235 Aggregate effect sizes for each study were calculated by the 'aggregate' function from the *metafor*
236 package in R (Viechtbauer, 2010). Compound symmetric structure (CS) and a conservative rho
237 value of 0.7 were applied as per Rosenthal (1986). Data are visualized using funnel plots (Begg and
238 Mazumdar, 1994; Sterne and Egger, 2001) with standard error (SE) as a measure of uncertainty.

239

240 2.5 Data analysis

241 The meta-analysis was performed on the extracted data to estimate effect sizes in each
242 study using the *Meta-Essentials* tool in R (Suurmond et al., 2017). Standardized mean differences
243 and 95% confidence intervals (Hedge's G) were calculated from the mean metabolite
244 concentration change from baseline and/or the percentage change from baseline (% change), as
245 well as through their standard deviation, allowing us to compare data reported in different units.
246 If not specified, the first rest period was selected as baseline condition to calculate the mean
247 difference for all fMRS designs (block, event-related and time course data).

248 Since data extracted from time courses are considered dependent, their effect sizes should
249 be considered dependent as well. Therefore, time course data were first analysed separately and
250 then sub-grouped within-study with a random variance component (Tau) weighting separately for
251 each sub-group (Hak et al., 2016; Suurmond et al., 2017). Studies that did not allow for effect size
252 calculation due to missing information (e.g., concentration or %change) were included in the
253 systematic review but not in the meta-analysis. Heterogeneity of data was evaluated using I^2
254 (Higgins et al., 2003). The I^2 statistic is an estimate of proportion of variance in effect size that
255 reflects real heterogeneity. I^2 is a relative measure with a range from 0 to 100. Low I^2 suggests no
256 heterogeneity in data and no effect of moderator or potential clustering within the data. A high I^2
257 suggests there are external factors and biases driving the dispersions of effect sizes, which should
258 result in further sub-group analysis (Hak et al., 2016; Borenstein et al., 2021).

259 Most of the effect size estimates extracted in this current study consisted of time series
260 data, or several datapoints came from a single study (i.e., multiple outcomes from the same
261 participants, for example, rest versus stimulation conditions). This led to statistical dependency
262 between measures, which can lead to errors in variance estimation of the combined effect size


263 (Borenstein et al., 2021). To take the relationships among outcomes into account, robust variance
264 estimation (RVE) was used. RVE has the advantage of approximating the dependence structure
265 rather than requiring exact dependence values between effect sizes, as these are unknown for
266 most of the studies included (Pustejovsky and Tipton, 2021). We used a conservative correlation
267 coefficient of 0.7 for all observations (i.e. pre- and post- observations; time course data) in
268 accordance to Rosenthal (1986)'s recommendations.

269 Our main aim was to identify general patterns in the fMRS responses of GABA, Glu and Glx.
270 We then sub-grouped the data and analysed it based on type of stimulation, type of paradigm (i.e.,
271 block or event-related), and acquisition and analysis parameters (i.e., time, number of transients
272 per time point). Beyond stimulation type we also analysed the data by brain area (region of
273 interest). Because of variation in voxel location and limited available data for specific voxels we
274 opted to analyse these data by region to ensure collation of data. We grouped the ROIs to optimize
275 the number of studies yet retain a semblance of functional relevance. For example, motor cortex
276 and medial prefrontal cortex were categorized as 'frontal region'. We were also interested to
277 establish whether there was an association between effect size and quality of acquisition (based
278 on the MRS-Q). We first performed subgroup analysis on high-quality versus low-quality studies.
279 We then estimated the correlation coefficient between effect size and number of transients and
280 voxel size using Spearman's rho. Finally, we explored effect size as function of time using LOESS
281 (locally weighted least squares regression) fitting to investigate the non-linear trend of metabolite
282 changes over the course of an acquisition, as an exploratory step to inform on potential temporal
283 dynamics of the metabolite response (Ruppert and Wand, 1994). We do not expect this to be
284 linear, nor do we have any a priori expectations regarding the non-linear trajectory. Only
285 metabolite levels during stimulation periods were taken into account for this analysis; metabolite
286 levels during breaks or periods of rest in between stimulation periods were excluded. The start of
287 MRS acquisition was considered as $t = 0$ s.

288 **3. Results**

289 **3.1 Study selection**

290 The initial search returned 3,385 studies. After automatic removal of duplicates, 3,383 studies
291 were eligible for abstract screening. 3,329 studies were excluded in the abstract screening stage
292 for the following reasons: additional duplicate studies (n = 538); irrelevant topic (n = 2,778); and
293 animal studies (n = 13). This resulted in 54 studies eligible for full-text screening, resulting in an
294 additional four studies excluded due to insufficient detail, and one study excluded due to it being
295 a meta-analysis. Finally, a total of 49 studies were included in this study. A PRISMA flow diagram
296 can be found in Figure 1.



297

298 Figure 1: PRISMA flow diagram (Page et al., 2021; Haddaway et al., 2022)

299

300 **3.2 Study characteristics**

301 **3.2.1 Spectroscopy**

302 Thirty-one of the fMRS studies were performed on 3 T MR-systems, 15 at 7 T, two studies were
303 performed at 4 T, and one study at 1.5 T. The most commonly (18 studies) used non-spectral-
304 editing sequence was PRESS (Bottomley, 1984; Klose, 2008) six studies used STEAM, and five
305 studies used sLASER. For spectral-editing sequences, 10 studies used MEGA-PRESS, six used
306 SPECIAL, two studies used MEGA-sLASER, and one study used each of BASING or STRESS. Two
307 studies reported the use of more than one editing sequence (Table 1). To measure fMRS GABA,
308 10 studies used MEGA-PRESS, three studies used SPECIAL, two studies used MEGA-sLASER, two
309 studies used MEGA-sLASER, two studies used sLASER and one study used STEAM. To measured
310 Glu and Glx, 18 studies used PRESS, 10 studies used MEGA-PRESS, six studies used STEAM, six
311 studies used SPECIAL, five studies used sLASER, one study used each of BASING or STRESS.

312 3.2.2 *Neurometabolites*

313 Fifteen studies investigated only Glu levels, seven studies investigated only Glx, nine studies
314 reported both Glu and Glx levels. Seven studies investigated both Glu and GABA, while ten studies
315 investigated both Glx and GABA, and one study reported only GABA. See Table 1 for details.

316 3.2.3 *Stimulus domains and brain regions*

317 We grouped studies into 8 stimulus domain categories. These domains were visual (n = 20),
318 pain (n = 8), learning (n = 7), cognition (n = 5), motor (n = 4), stress (n = 2), tDCs (n = 1), and exercise
319 (n = 3). Studies were considered to fall into the visual domain if they contained visual stimulation
320 (i.e., flashing checker board, rotating checker board, visual attention tracking, and video clips) the
321 pain domain if they contained stimulus that elicit pain (i.e., heat pain, dental pain and electric
322 shock) learning domain if they contained learning paradigm (i.e., object recognition,
323 reinforcement learning, n-back task (for short-term memory/implicit learning and working
324 memory) , cognition if they contained cognitive task (i.e., Stroop task, imaginary swimming and
325 categorization of either object or abstract stimuli) , motor if they contained motor response (i.e.,
326 hand clenching and finger tapping), stress if they contained psychological stress, and
327 pharmacological stress and exercise if they contained measurement of evaluation of heart rate to
328 exercise.

329 The studies were grouped in six different brain regions of interest (ROI). The most studied ROI
330 was the occipital ROI for Glu/Glx and GABA. Additional details of MR-parameters and fMRS
331 experiment designs are presented in Table 1. Figures 2A and 2B summarise studies by brain ROIs
332 investigated for Glx/Glu and GABA, respectively, and additionally reports on stimulus domain.

333 Table 1. Studies characteristic

Author name	Neurometa bolites	Design	Stimulatio n	Area	vox el (ml)	Sample size/Age (SD)/Gender (%) Female)	Scanner/Strength/Sequ encer/(TR/TE) ms/Number of transients	MRS-Q QUALITY
Apšvalka et al., (2015)	Glu	block/e vent- related	Learning	Left LOC	8	13/ 21.85 (1.91) yrs/ 53.85%	Philips/ 3T/ PRESS/(1500/105)/264	High
Archibald et al., (2020)	Glu,Glx	block	Pain	ACC	11.2 5	18/ 26.28 (3.68) yrs/ 50%	Philips/3T/PRESS/(4000/ 22)/32	High
Bednářík et al.,(2015)	Glu,GABA	block	Visual	V1	8	15/ 33(13) yrs/ 53.33%	Agilent/7T/sLASER/(500 0/26)/32	High
Bezalel et al., (2019)	Glx, GABA	event- related	Learning	dACC	10	37/ Med=26 yrs/56.76%	Siemens/3T/MEGA- PRESS/(2000/68)/144	Low
Boillat et al., (2020)	Glu, GABA	block	Visual	OC	5.83 2	Nc=21/Ne=41/24 .95(2.83) yrs/36.59%	Siemens/7T/SPECIAL /(7500/16)/176	High
Chen et al., (2017)	Glx, GABA	block	Motor	M1	9	13/26(3) yrs/50%	Philips/7T/MEGA- sLASER/(5000/72)/40	High

Chiappelli et al., (2018)	Glu	block	Pain	dACC	12	21/37.6(15.2) yrs/42.86%	Siemens/3T/PR-STEAM/(2000/6.5, TM=10)/128	High
Cleve et al., (2015) A	Glx, GABA	event-related	Pain	ACC	8.64	Nc=15/Ne=10/24 (1.6) yrs/100%	Siemens/3T/MEGA-PRESS/(3000/68)/128	Low
Cleve et al., (2015) B	Glx, GABA	event-related	Pain	OC	10.5	14/24(1.6) yrs/100%	Siemens/3T/MEGA-PRESS/(3000/68)/128	Low
Cleve et al., (2017)	Glx, GABA	block	Pain	Left insular cortex	15.6	27/24(3) yrs/0%	Siemens/3T/MEGA-PRESS/(1800/68)/192	Low
Coxon et al., (2018) A	Glx, GABA	block	Excercise	SM	8	10/29.4(10.72) yrs/20%	Siemens/3T/MEGA-PRESS/(1500/68)/96	Low
Coxon et al., (2018) B	Glx, GABA	block	Exercise	DLPFC	8	8/29.4(10.72) yrs/20%	Siemens/3T/MEGA-PRESS/(1500/68)/96	Low
Dennis et al., (2015)	Glu	block	Exercise	OC	8	11 /30 yrs/63.64%	Siemens/7T/SPECIAL/(4500/8.50)/60	High
Dwyer et al., (2021)	Glu, GABA	block	Visual	OC	19.3	20 /29 yrs / 45% 44	GE/3T/MEGA-PRSS/(1500/68)/600	High
Fernandes et al., (2020)	Glu	block	Visual	V1	12	6 /25-30 yrs/50% 0/144)	Philips/7T/sLASER/(500/60)	High

Floyer et al., (2006)	GABA	block	Learning	M1	8	13/25 yrs/ n/a	Varian/ 3T/MEGA-PRESS/(<i>/68)/192	Unsure
Frank et al., (2021) A	Glx, GABA	block	Visual	PIVC	15.6 25	20/24(1) yrs/ 70%	Siemens/3T/PRESS/(300 0/30)/128	High
Frank et al., (2021) B	Glx, GABA	block	Visual	PIVC	15.6 25	20/24(1) yrs/70%	Siemens/3T/MEGA-PRESS/(1500/68)/256	Low
Gussew et al., (2010)	Glu	event-related	Pain	insular cortex	2	6/ 31.1(11.1) yrs/100%	Siemens/3T/PRESS/(500 0/30)/32	Low
Gutzeit et al., (2011)	Glu, Glx	block	Pain	insular cortex	15.0 4	10/ 24-51 yrs /0%	Philips/3T/PRESS/(2000/ 30)/80	High
Gutzeit et al., (2013)	Glu, Glx	block	Pain	insular cortex	9.6	16/33.1 yrs/0%	Philips/3T/PRESS/(2000/ 30)/96	High
Hasler et al., (2010)	Glx	block	Stress	PFC	18	10/ 28.7 (9) yrs/ 40%	GE / 3 T/ MEGA-PRESS / (1500/68)/ 128	High
Huang et al., (2015) A	Glx	block	Cognitive	MPFC	9	46/ 18-29 yrs/ 56.52%	Philips / 3 T/ PRESS / (3000/24)/ 128	High
Huang et al., (2015) B	Glx	block	Cognitive	auditory cortex	9.36	47/ 18-30 yrs/ 56.25%	Philips / 3 T/ PRESS / (3000/24)/ 128	High
Ip et al., (2017)	Glu	block	Visual	OC	8	18/ 28.71(5.62) yrs / 50%	Siemens/7T/sLASER/(40 00/36)/ 728 (sliding	High (Low* for moving

							window: width= 4, moving average =3) transients analysis)	
Jahng et al., (2016)	Glu, Glx	block	Visual	parietal– posterior cingulate cortex	15.6 25 (5.79) yrs/ 24 Old healthy 69.67 (6.58) yrs/ 42.55%	23 Yong 27.82	Philips / 3 T/ PRESS / (2000/35)/ 36	High
Jelen et al., (2019)	Glu, Glx	block	Learning	ACC	12	14/ 33.8 (10.5) yrs/ 50%	GE / 3 T/ PRESS / (2000/ 105)/ 8	Low
Kim et al., (2013b)	Glx	block	Visual	ACC	7.2	23/ 38.4 (10) yrs/ 100%	Siemen / 3 T/ PRESS / (2000/30)/ 96	High
Kim et al., (2014)	Glx	block	Visual	ACC	7.2	20/ 40.6 (8.8) yrs/ 100%	Siemen / 3 T/ PRESS / (2000/30)/ 96	High
Kolasinski et al., (2019)	Glu, GABA	block	Motor	M1	8	Nc = 14, Ne = 18/ 24.3 (4.8) yrs/ 37.5%	Siemens / 7 T/ sLASER / (36/5000)/ 64	High
Koush et al., (2021a)	Glx, GABA	block	Visual	VC, PCC	14 (VC) , 27	20/ 29 (8.5) yrs/ 50%	Bruker spectrometer / 4 T/ MEGA-sLASER / (2700/70.7)/ 360	High

(PC C)								
Kühn et al., (2016)	Glu, GABA	block	Cognitive	ACC	17.5	19/ 25 (1.7) yrs/ 57.89%	Siemens / 3 T/ SPECIAL / (3000/8.5)/ 256	Low
Kurcyus et al., (2018) A	Glx, GABA	block	Visual	OC	15.6 25	25/ 26.9 (2.65) yrs/ 28%	Siemens / 3 T/ MEGA- PRESS / (2000/68)/ 256	High
Kurcyus et al., (2018) B	Glx, GABA	block	Resting	OC	15.6 25	25/ 27.4 (3.14) yrs/ 52%	Siemens / 3 T/ MEGA- PRESS / (1500/68)/ 256	High
Lally et al., (2014)	Glu	event- related	Cognitive	LOC	8	14/ 23.79 (3.9) yrs/ 42.86%	Siemen / 3 T/ PRESS / (3000/40)/ 303	High
Lin et al. , (2012)	Glu, GABA	block	Visual	DLPFC	8	9/ 25 (3) yrs/ 30%	Philips / 7 T/ STEAM / (3000/15)/ 32	High
Lynn et al., (2018a)	Glu	block	Visual	DLPFC	4.5	9/ 24.3 (3.5) yrs/ 0%	Siemen / 3 T/ PRESS / (4000/32)/ 8	Low
Maddock et al., (2011)	Glx	block	Excercise	visual cortex	18.7 5	8/ 25 yrs/ 62.5% J-editing / (1500/144)/ 50	GE / 1.5 T/ interleaved, J-editing / (1500/144)/	Low
Mangia et al., (2007)	Glu	block	Visual	visual cortex	8.8	12/ 19-26 yrs/ n/a%	Magnex Scientific / 7 T/ STEAM / (5000/6 ms, TM = 32)/ 64	High

Martinez- Maestro et al., (2019)	Glu	block	Visual	visual cortex	8	14/ 18-33 yrs/ 57.14%	Siemens / 7 T/ sLASER / (4000/40)/ 320	High
Mekle et al., (2017)	Glu, GABA	block	Visual	visual cortex	8	20/ 29 yrs/ 45%	Siemens / 7 T/ SPECIAL / (5000/6.0)/ 128	High
Michels et al., (2012)	Glx, GABA	block	Learning	left DLPFC	30	16/ 28 yrs/ 43.75%	GE / 3 T/ MEGA-PRESS / (1800/68)/ 320	High
Mullins et al., (2005)	Glu, Glx	block	Pain	Bilateral ACC	8	8/ 24 yrs/ n/a	Varian / 4 T/ STEAM / (2000/20)/ 256	High
Schaller et al. (2013)	Glu	block	Visual	visual cortex	8.8	Nc = 4, Ne = 6/ 20-28 yrs/ 10%	Siemens / 7 T/ SPECIAL/ (5000/6)/ 80	Low
Schaller et al., (2014)	Glu	block	Motor	motor cortex	5.78	11/ 18-26 yrs/ 18.18%	Siemens / 7 T/ SPECIAL / (7500/12)/ 176	High
Siniatchkin et al., (2012)	Glx	block	Visual	visual cortex	8	10/ 20.3 (3.2) yrs/ 60%	Philips / 3 T/ PRESS / (2000/37)/ 128	High
Stagg et al., (2009)	Glx, GABA	block	tDCS	L sensorimotor cortex	8	11/ 27 yrs/ 90.91%	Siemens/Varian MRI system / 3 T/ MEGA-PRESS / (<i>/68</i>)/ 96	Unsure

Stanley et al., (2017)	Glu	block	Learning	Hippocampus	6.12	16/ 25 (2) yrs/ 43.75%	Siemens / 3 T/ PRESS with OVS / (3375/23)/ 32	Low
Taylor et al., (2015a)	Glu, Glx	block	Cognitive	ACC	8	16/ 23.9 (4.7) yrs/ 31.25%	Agilent / 7 T/ STEAM / (3000/10)/ 80	High (Low* for moving transients analysis)
Taylor et al., (2015b)	Glu, Glx	block	Cognitive	ACC	8	7/ 39.8 (3.8) yrs/ n/a%	Agilent / 7 T/ STEAM / (3000/10)/ 80	High
Vijayakumar et al., (2020)	Glx	block	Learning	DLPFC	8	22/ 62.55 (6.6) yrs/ 50%	GE / 3 T/ PRESS / (2000/30)/ 128	High
Volovyk and Tal et al., (2020)	Glu, Glx	block	Motor	left sensory-motor cortex	6	41/ 29.7 (4.7) yrs/ 56.1%	Siemens / 3 T/ PR- STRESS / (2000/15 ms)/ 608,768	Low
Woodcock et al., 2018 (2018)	Glu	block	Learning	DLPFC	4.5	16/ 18-30 yrs/ 43.75%	Siemens / 3 T/ PRESS / (4000/23)/ 16	Low


Woodcock et al., (2019)	Glu	block	Learning/ Stress	DLPFC	4.5	19/ 27.5 (3.9) yrs/ 15.79%	Siemens / 3 T/ PRESS / (4000/23)/ 16	Low
-------------------------------	-----	-------	---------------------	-------	-----	-------------------------------	---	-----

334


335 <i>:insufficient information; ACC: Anterior cingulate cortex; dACC: Dorsal Anterior cingulate cortex; DLPFC: Dorsolateral prefrontal cortex; GABA:
336 Gamma aminobutyric acid; Glu: Glutamate; Glx: Glutamate + Glutamine; LOC: Lateral occipital complex; LOC: Lateral Occipital Cortex; M1: primary
337 mortor cortex; MC: Motor cortex; MEGAPRESS: MEscher-garwood point-resolved spectroscopy; MPFC: Medial prefrontal cortex; MPFC: Medial
338 prefrontal cortex; ms: mill-second; OC: Occipital cortex; PCC: Posterior cingulate cortex; PFC: Prefrontal cortex; PIVC: Parieto-insular vestibular
339 cortex; PRESS: Spin-echo point-resolved spectroscopy; PR-STRESS: STEAM+PRESS pulse sequence; SC: Somatosensory cortex; sLASER: Semi
340 localization by adiabatic selective refocusing; SM: Sensorimotor cortex; SPECIAL: spin-echo full intensity acquired localized; STEAM: Stimulated echo
341 acquisition mode; T: tesla; tDCS: Transcranial direct current stimulation; V1: primary visual cortex; yrs: years old.

342

A) Glu/Glx



B) GABA



343

344 Figure 2: (A) Brain ROIs and stimulus domains of included fMRS studies of Glu/Glx. (B) Brain ROIs
345 and stimulus domains of included fMRS studies of GABA. Note that brain ROIs were generalized
346 by the authors to optimize inclusion.

347

348 **3.3 Quality assessment**

349 **3.3.1 MRS-Q**

350 Most studies ($n = 31/49$, 63.3%) satisfied the MRS-Q criteria of standardized reporting and best
351 practice and were assessed to be of high quality (Figure 3A). Eighteen studies (36.7%) were
352 assessed as low quality due to inadequate MRS parameters according to MRS-Q, mostly due to an
353 insufficient number of transients or small voxel sizes (see Discussion for further consideration of
354 using baseline MRS quality assurance approaches for fMRS). Among these low-quality studies, nine
355 used spectral-edited fMRS(Maddock et al., 2011; Schaller et al., 2013; Cleve et al., 2015, 2017;
356 Kühn et al., 2016; Coxon et al., 2018; Bezalel et al., 2019; Volovyk and Tal, 2020; Frank et al., 2021),
357 while eight were non-edited (Gussew et al., 2010; Taylor et al., 2015a; Betina Ip et al., 2017;
358 Stanley et al., 2017; Lynn et al., 2018a; Woodcock et al., 2018, 2019; Jelen et al., 2019). For high
359 quality studies, nine studies used spectral-edited fMRS (Hasler et al., 2010; Michels et al., 2012;
360 Schaller et al., 2014; Dennis et al., 2015, 2015; Chen et al., 2017; Mekle et al., 2017; Kurcyus et al.,
361 2018; Boillat et al., 2020; Dwyer et al., 2021) and 24 were non-edited (Mullins et al., 2005; Mangia
362 et al., 2007; Gutzeit et al., 2011, 2013; Lin et al., 2012; Siniatchkin et al., 2012; Kim et al., 2013b,
363 2014; Lally et al., 2014; Apšvalka et al., 2015; Bednářík et al., 2015; Huang et al., 2015; Taylor et
364 al., 2015b, 2015a; Jahng et al., 2016; Betina Ip et al., 2017; Chiappelli et al., 2018; Kolasinski et al.,
365 2019; Martínez-Maestro et al., 2019; Archibald et al., 2020; Fernandes et al., 2020; Vijayakumari
366 et al., 2020; Frank et al., 2021; Koush et al., 2021b). Two edited-fMRS studies (Floyer-Lea et al.,
367 2006; Stagg et al., 2009) reported insufficient information regarding the MRS parameters and
368 were identified as 'unsure'.

369


370 **3.3.2 RoBANS**

371 The risks of biases assessed using the RoBANS are summarized in Figure 3B. According to the
372 RoBANS assessment, all but one study was considered to have a high risk of bias due to non-
373 blinding of outcome, primarily due to participants or experimenters being aware of
374 receiving/delivering a functional paradigm. Only one study explicitly reported blinding of outcome.

375 Given the nature of fMRS experiment as a pre-post intervention study, some fMRS experiment
376 designs might be impossible to blind. While there may be potential bias due to the fMRS examiner
377 or participant being aware of the stimulus being given, the order of stimuli is often unknown to
378 participant and therefore 'blind' to the stimulus paradigm. Yet, this bias needs to be considered
379 as it may impact the results (e.g., participant may behave differently when the purpose is known,
380 experiments may bias their analysis based on the paradigm). Blinding criteria are likely more
381 relevant for pharmacological studies than for typical fMRS experiments.

382 fMRS studies are often required to exclude data with unsatisfactory spectral quality. While
383 this is common in MRS, based on the RoBANS criteria, studies with incomplete outcome data
384 would be identified as high risk. Given above criteria, 55.1% of studies were considered high-risk.
385 Twenty-two studies (44.9%) stated that all data were included. Two studies (4.1%) were of high
386 risk of bias for selective outcome reporting as they did not fully report all available outcomes. Bias
387 of inadequate measurement was also identified via the MRS-Q by assessing whether studies
388 reported adequate MRS parameters; 70% of all studies included were assessed to be at low risk of
389 bias in this domain. No study reported potential bias in selection of participants.

390



391

392 Figure 3: (A) MRS-Q assessment of MRS studies (B) Risk of Bias Assessment Tool for
393 Nonrandomized Studies (RoBANS) quality.

394 3.4 Publication bias

395 The summary for the Egger's and Trim-and-fill test for publication bias are showed in Table 2.

396

397 Table 2. A summary of the publication bias results from both Egger's test and Trim-and-fill test

Data	Metabolite	Estimate aggregated effect size	Egger's test	Adjusted estimate effect size	Trim-and-fill test
Mean	Glu/Glx	0.09	Bias p < 0.001	-0.791	No case added
	Glu	0.21	Bias p < 0.001	0.857	No case added
	Glx	0.07	Bias p = 0.034	-0.478	No case added
	GABA	-0.26	No bias p = 0.302	-0.881	No case added
%Change	Glu/Glx	0.12	Bias p < 0.01	-1.607	No case added
	Glu	0.11	Bias p < 0.01	-1.707	No case added
	Glx	0.14	Some bias p = 0.092	-0.863	No case added
	GABA	-0.10	No bias p = 0.887	-0.198	No case added

398

399 3.4.1 *Egger's regression test and funnel plot*

400 Egger's regression test (Egger et al., 1997) is a quantitative asymmetry test based on a simple
401 regression model. The funnel plot illustrates the effect size of each study on the x-axis and
402 standard error on the y-axis, without the publication bias the studies should roughly followed the
403 funnel shape with symmetric distribution of datapoints (Lin and Chu, 2018). No asymmetry in small
404 and large effect sizes was found for GABA (both %change_{GABA} and mean_{GABA}). However, Egger's
405 test suggested significant asymmetry ($p < 0.05$) for Glu/Glx, as well as for Glu and Glx when
406 analyzed separately, except for %change_{Glx}. Supplementary Table 2 shows the results from the
407 Egger's regression test including the estimated effect sizes adjusted for publication bias.
408 Supplementary Figure 1 shows the funnel plot using SE as a measure of uncertainty, color coded
409 by stimulus domain. These data suggest that studies of Glu/Glx were asymmetrical due to an
410 absence of small effect size positive direction studies.

411

412 *3.4.2 Trim-and-fill*

413 The trim-and-fill method is a non-parametric test that was used to visualize and correct data
414 asymmetry due to publication bias (Duval and Tweedie, 2000). The principle of the method is to
415 'trim' the studies with publication bias causing plot asymmetry, and to use the trimmed funnel
416 plot to estimate the estimated the true centre of the funnel plot, then 'filling' or added the
417 trimmed studies and their missing counterpart studies (not reported due to publication bias).
418 Based on the method, no study was added via the trim-and-fill test; therefore, the estimated
419 effect sizes remained the same. All data demonstrated moderate to high heterogeneity with I^2
420 values of 60% - 90% (Supplementary Table 3). This means that the variability and inconsistency
421 across study are from the true heterogeneity in the data and not by chance (Higgins et al., 2003).
422 Trim-and-fill analysis suggested there were no potential missing studies due to bias
423 (Supplementary Figure 2). Due to presence of between-study heterogeneity in this current study,
424 the interpretation of these results needs to be treated with care (Terrin et al., 2003; Ioannidis
425 and Trikalinos, 2007; Shi and Lin, 2019).

426

427 **3.5 Meta-analysis**

428 *3.5.1 Effect of fMRS-design*


429 *Neurometabolite levels across all studies*

430 When we considered change in metabolite levels across studies regardless of stimulus
431 domain, brain ROI, or other factors (e.g., voxel size, number of transients), mean_{Glu} and mean_{Glx}
432 increased significantly compared to the respective baseline condition (Hedge's $G_{\text{Glu_mean}} = 0.37$,
433 95% CI: 0.09 – 0.645, $I^2 = 86.83$ and $G_{\text{Glx_mean}} = 0.29$, 95% CI: 0.035 – 0.555, $I^2 = 87.71$ respectively).
434 The *percentage* change between baseline and active conditions in Glu was positive on average
435 (Hedge's $G_{\text{Glu_pct}} = 0.47$, 95% CI: 0.158 – 0.789, $I^2 = 82.81$). No significant change was observed for
436 GABA studies for either mean or percentage change when compared to baseline (Figure 4A).


437 *Neurometabolite levels by type of paradigm*

438 When effect sizes were computed by type of paradigm regardless of brain ROI and stimulus
 439 domain, block designs showed lower confidence intervals in effect size relative to event-related
 440 designs and a significant overall positive change in Glu/Glx for both mean and %change (Hedge's
 441 $G_{Glu/Glx\text{-mean}} = 0.27$, 95% CI: 0.064 – 0.475, $I^2 = 86.28$; Hedge's $G_{Glu/Glx\text{-%change}} = 0.36$, 95% CI: 0.124 –
 442 0.605, $I^2 = 86.28$) (Figure 4B). A significant reduction in mean GABA was observed for event-related
 443 designs (Hedge's $G_{GABA} = -0.76$, 95% CI: -1.285 – -0.227, $I^2 = 0.11$), but no significant change was
 444 observed for block paradigms. It must be noted that the significant effect observed here is of one
 445 study only, thus the interpretation of the result must be treated with care.

(A) Overall effect sizes by type of data and metabolite irrespective of stimulus domains



(B) Overall effect sizes by type of paradigm and metabolite



446

447 Figure 4: (A) Overall effect sizes by type of data and metabolite irrespective of stimulus domains.
 448 (B) Overall effect sizes by type of paradigm and metabolite. N: number of studies included; Glu/Glx:
 449 Glu or Glx studies; I^2 : I^2 index for heterogeneity. A high I^2 suggests there are external factors and


450 biases driving the dispersion of effect sizes. *Statistically significant at $p < 0.05$, and at $p < 0.01$
451 when the degrees of freedom < 4 for RVE t-tests.

452

453 *3.5.2 Neurometabolite levels by stimulus domains*

454 All stimulus domains that demonstrated a significant change from baseline contained only
455 one individual study with 3 to 9 within-study outcomes (i.e., were driven by single studies that had
456 multiple results at different timepoint, metabolite changes as a function of time or different types
457 of stimuli within a single study). The percentage in GABA level increased positively during exercise
458 ($\text{Hedge's } G_{\text{GABA-mean}} = 0.46$, 95% CI: $0.023 - 0.906$, $I^2 = 0.7$). On the other hand, the $\%change_{\text{Glu/Glx}}$
459 was positive during learning ($\text{Hedge's } G_{\text{Glu/Glx-} \%change} = 0.29$, 95% CI: $0.106 - 0.469$, $I^2 = 0.23$), mean
460 GABA showed negative change from baseline ($\text{Hedge's } G_{\text{GABA-mean}} = -0.76$, 95% CI: $-1.285 - -0.227$,
461 $I^2 = 0.11$) during learning. Mean GABA and $\%change$ in GABA showed significant change in the
462 opposite direction in the motor domain ($\text{Hedge's } G_{\text{GABA-mean}} = -0.76$, 95% CI: $-1.485 - -0.044$, $I^2 =$
463 0.6 ; $\text{Hedge's } G_{\text{GABA-} \%change} = 0.32$, 95% CI: $0.184 - 0.459$, $I^2 = 0$). Stress stimulation was associated
464 with a significant negative change for GABA ($\text{Hedge's } G_{\text{GABA-mean}} = -0.87$, 95% CI: $-1.609 - -0.129$, $I^2 =$
465 0.69). During transcranial direct current stimulation, GABA showed a negative $\%change$ ($\text{Hedge's } G_{\text{GABA-} \%change} = -0.12$, 95% CI: $-0.238 - -0.006$, $I^2 = 0$). There were no significant changes related to
466 visual stimulation for any measure of Glu/Glx and GABA (Figure 5). Again, it must be highlighted
467 that only 1-2 studies were included in these results with statistical significance, thus these findings
468 need to be interpreted cautiously.

469




471

472 Figure 5: Overall effect sizes by type of stimulus and metabolite. N: number of studies included;
 473 Glu/Glx: Glu or Glx studies; I^2 : I^2 index for heterogeneity. A high I^2 suggests there are external
 474 factors and biases driving the dispersions of effect sizes. * Statistically significant at $p < 0.05$, and
 475 at $p < 0.01$ when the degrees of freedom < 4 for RVE t-tests.

476

477 3.5.3 Neurometabolite levels by ROI studied

478 When we investigated the neurometabolites by ROI, only a few studies were included for
479 each metabolite. Across neurometabolites, regardless of stimulus domain, every ROI except for
480 the limbic ROI showed a significant difference in neurometabolite levels compared to the baseline
481 condition. The occipital ROI comprised most of the studies included (n = 22 across metabolites).
482 Pooled effect sizes from six studies in occipital ROIs observed an overall increase by %change of
483 Glu/Glx (Hedge's $G_{Glu/Glx}$ -%change = 0.84, 95% CI: 0.089 - 1.588, $I^2 = 88.73$). This was surprising since
484 stimulation in the visual domain themselves showed no significant effect. This may be because the
485 effect of visual stimulation was not only tested in visual cortex but across different ROIs (see Figure
486 2 and Table 1). Significant increases compared to the baseline condition were also observed for
487 frontal %change_{GABA} (Hedge's G_{GABA} -%change = 0.35, 95% CI: 0.046 – 0.649, $I^2 = 80.86$) and insular
488 mean_{Glu/Glx} level (Hedge's $G_{Glu/Glx}$ -mean = 0.52, 95% CI: 0.094 – 0.95, $I^2 = 75.97$). Due to limited
489 available data, temporal and parietal ROI only had one study included for each analysis, except for
490 percentage change in parietal GABA. While significant differences were observed, these data show
491 very low heterogeneity ($I^2 = 0 – 0.23$). This might suggest a potential bias in over- or under-
492 estimating the observed effects since these results are from within-study outcomes. Data by ROIs
493 are shown in Figure 6.



494

495 Figure 6: Overall effect sizes by ROIs. Glu/Glx: Glu or Glx studies; N: number of studies included;
 496 I^2 : I^2 index for heterogeneity. A high I^2 suggests there are external factors and biases driving the
 497 dispersions of effect sizes. * Statistically significant at $p < 0.05$, and at $p < 0.01$ when the degrees
 498 of freedom < 4 for RVE t-tests.

499


500 3.5.4 Effect sizes in relation to time

501 Several studies had time-course data available, and we were therefore able to explore
 502 effect sizes based on 'time-in-acquisition' (see Figure 7). The results show different temporal
 503 fluctuation for GABA/Glu/Glx in different stimulus domains. The fitted line (LOESS) suggests
 504 potential metabolic response patterns; GABA tends to start high but then decreases with
 505 increasing time-in-acquisition in learning paradigms. For Glu/Glx_{mean}, three studies were included
 506 for exercise stimulus and one study was included for each of visual, learning and stress. For
 507 mean_{GABA}, one study was included for visual stimulus. For %change_{Glu/Glx}, four studies were
 508 included for visual stimulus, two studies for learning, and one study each for motor and cognitive.
 509 For %change_{GABA}, one study was included for motor stimulus. The %change_{Glu/Glx} tends to


510 increase with increasing stimulation for visual paradigms only. There were no clear patterns for
511 mean_{GABA} and mean_{Glu/Glx}. It should be noted that while this is interesting, the amount of available
512 data included is too small to make a firm conclusion.

513

Mean value data



% Change data



514

515 Figure 7: Effect size of each study in relation to time of data acquisition during fMRS. Only
516 metabolite levels during stimulus periods were included. Time 0 s is considered the start of the
517 MRS acquisition. The size of dots represents the weight of the effect size.

518

519


520 **3.6 Effect of fMRS-parameters**

521 *3.6.1 Effect of quality based on the MRS-Q*

522 Supplementary Figure 3 illustrates data when only 'high quality' studies were included. Generally,
523 Glu/Glx show a positive trend while GABA shows a small negative trend for mean_{GABA} compared
524 to baseline. These findings are in agreement with section 3.5.1 where we did not consider study
525 quality. Unlike in section 3.5.1, however, the change in mean_{Glu/Glx} was not significant from
526 baseline, while %change_{Glu/Glx} was significant, with higher effect size from baseline compared to
527 3.5.1 (Hedge's $G_{Glu/Glx\text{-mean}} = 0.24$, 95% CI: $-0.066 - 0.553$, $I^2 = 85.04$, $p = 0.045$). GABA data show
528 an overall lower effect for both mean and %change and did not reach statical significance,
529 consistent with section 3.5.1.

530 Figure 8 shows data for Glu/Glx and GABA by stimulus domains across high-quality studies only.
531 Several domains contained only a single high-quality study, therefore, results in domains such as
532 stress (Glx and GABA) and motor (GABA) remained relatively the same. Mean_{Glu} shows a difference
533 for the motor domain when only high-quality studies were included, indicating an increase of Glu-
534 mean compared to the baseline condition (Hedge's $G_{Glu\text{-mean}} = 0.37$, 95% CI: $0.004 - 0.743$, $I^2 = 0$).
535 Exercise, learning, pain, and visual domain remained non-statistically significant for all metabolite
536 types.

537



538

539 Figure 8: Meta-analysis of only 'high quality' studies as assessed by MRS-Q pooled based on
 540 stimulus domains. N: number of studies included; I^2 : I^2 index for heterogeneity. A high I^2 suggests
 541 there are external factors and biases driving the dispersions of effect sizes. *Statistically significant
 542 at $p < 0.05$, and at $p < 0.01$ when the degrees of freedom < 4 for RVE t-tests.

543


544 3.6.2 Effect of number of transients and voxel size

545 First, we assessed whether effect size was correlated with the number of transients and
 546 voxel size. The number of transients mentioned here is the number of transients that was
 547 averaged across for metabolite quantification (e.g., per acquisition block or per one window width
 548 for sliding window analysis). There was statistically significant relationship between effect size and
 549 the number of transients for mean_{Glu} ($\rho = -0.3$, $p = 0.0062$). All other metabolites showed no
 550 significant relationship with number of transients ($\text{mean}_{\text{GABA}}$: $\rho = 0.021$, $p = 0.9$, mean_{Glx} : $\rho = -0.27$,
 551 $p = 0.084$). Percentage change in GABA (%change_{GABA}: $\rho = -0.21$, $p = 0.079$), Glu (%change_{Glu}: $\rho =$


552 -0.15, $p = 0.11$), and Glx (%change_{Glx}: $p = -0.26$, $p = 0.2$) showed no significant correlations between
553 number of transients and effect size (Figure 9).

554

Mean value data




% Change data



555

556 Figure 9: Relationship between effect size and number of transients used in included studies. The
557 size of each dot represents the weight of effect size. met: metabolites; GABA: γ -Aminobutyric acid;
558 Glu: Glutamate; Glx: Glutamine + Glutamate.


559 To analyse the association between effect size and number of transients, we binned
 560 studies based on the number of transients. Most of the studies used a number of transients in the
 561 range of 65-128 and 129-256 for metabolite quantification (n = 13 for each bin). A small increase
 562 in percentage GABA (Hedge's G_{GABA} -%change = 0.23 – 0.32) and a small decrease in mean_{GABA} (Hedge's
 563 G_{GABA} -mean = -0.76) were observed for studies with a limited number of transients (1-32 and 33-64).
 564 However, these significant results included data from only one study (Figure 10). The results were
 565 inconclusive when analysing these data by stimulus type, as only 1-4 studies were included for
 566 each stimulus type (Supplementary Figure 4).



567
 568 Figure 10: Influence of range of transient width on metabolite levels. N: number of studies
 569 included; I^2 : I^2 index for heterogeneity. A high I^2 suggests there are external factors and biases
 570 driving the dispersions of effect sizes. *Statistically significant at $p < 0.05$, and at $p < 0.01$ when the
 571 degrees of freedom < 4 for RVE t-tests.

572
 573 The relationship between voxel size and effect size was different based on type of data
 574 (mean or %change) (Figure 11). For fMRS studies reported in mean metabolite levels, the effect
 575 sizes showed a negative relationship with voxel size (mean_{GABA}: $p = 0.42$, $p = 0.012$; mean_{Glu}: $p =$

576 0.066, $p = 0.55$; mean_{Glx} : $p = -0.42$, $p = 0.0059$). Conversely, in studies reporting %change from the
577 baseline condition, we observed a positive relationship between effect size and voxel size for all
578 type of metabolite ($\% \text{change}_{\text{GABA}}$: $p = 0.12$, $p = 0.3$; ($\% \text{change}_{\text{Glu}}$: $p = 0.19$, $p = 0.043$; ($\% \text{change}_{\text{Glx}}$:
579 $p = 0.41$, $p = 0.039$). Only mean_{Glu} and $\% \text{change}_{\text{GABA}}$ did not demonstrate a significant relationship
580 with voxel size (Figure 11).



581

582 Figure 11. Effect size of each study in relation to voxel size in milliliters. The line represents a
583 linear regression line for visual purposes only. ρ : Spearman's rho; met: metabolites; GABA: γ -
584 Aminobutyric acid; Glu: Glutamate; Glx: Glutamine+Glutamate.

585

586

587 Discussion

588 1. Summary of the findings

589 We systematically evaluated and synthesized the fMRS literature on GABA and Glu/Glx to
590 date (mid 2021). Overall, results show a wide variability in effect sizes and directionality for both
591 Glu/Glx and GABA when generalized across design and stimulus domain. Most of the Glu/Glx

592 studies showed positive trends (increases) during stimulation compared to baseline (at rest), while
593 GABA studies generally showed negative trends (decreases) compared to baseline. The increase
594 in Glu/Glx levels is in agreement with several animal studies showing an association between
595 neuronal activation and Glu/Glx in response to task or stimuli (Just and Faber, 2019; Takado et al.,
596 2021), which also correlates with BOLD signal activation (Just et al., 2013; Baslow et al., 2016; Just
597 and Sonnay, 2017). Significant changes in Glu and Glx from baseline only had a small to average
598 effect size (Hedge's $G_{Glu \text{ and } Glx} = 0.29 - 0.47$). Although changes in GABA compared to baseline were
599 not statistically significant across studies, the general directionality of *decreased* GABA levels is
600 consistent with a previous narrative review by Duncan et al (2014) suggesting that GABA tends to
601 be negatively correlated with task-evoked neuronal responses, as well as with studies showing
602 that inhibition tends to decrease during repeated stimulation or learning (Stagg et al., 2011; Heba
603 et al., 2016; Kolasinski et al., 2019). Ultimately, this meta-analysis shows that current fMRS works
604 show large variety within domain and stimulus type, small effect sizes, and susceptibility to factors
605 beyond experimenter control. While standardised reporting is becoming more widespread in MRS
606 field, fMRS does not always adhere to the same principles and additional reporting standards need
607 to be developed. This includes thorough reporting stimulus details and analysis methods, including
608 open access to analysis code and stimulation paradigms, as these are likely driving the
609 heterogeneity as well. This review revealed several important factors that need to be considered
610 when performing and interpreting fMRS studies, which are detailed in the following sections.

611

612 2. Effect of fMRS design

613 2.1 Effect of fMRS paradigm: block paradigm or event-related

614 In the current meta-analysis, the magnitude of effect sizes was observed to be smaller for
615 block designs than event-related designs. This is in agreement with a previous meta-analysis of
616 fMRS of Glu (Mullins, 2018). However, block designs provided more consistent results for Glu/Glx
617 from tighter 95%CI of the averaged effect sizes compared to event-related designs, suggesting
618 that block paradigms may be better at capturing Glu/Glx changes. On the other hand, event-
619 related paradigms showed a wider range of confidence intervals compared to block design (event-

620 related: 95% CI of -0.23 to 5.59, Block: 95% CI of -0.406 – 0.605). Although speculative, perhaps
621 the most relevant difference between these two paradigms is that they are likely probing different
622 brain processes, i.e., fast-acting neurochemical response through event-related designs and
623 slower homeostatic processing or plasticity in block paradigms.

624 Block designs have the potential advantage of robust metabolite quantification as signal
625 averaging is performed during a sustained stimulus. Habituation and adaptation to repeated
626 stimulation with a potential summative effect likely plays a key role in block designs (Michels et
627 al., 2012; Betina Ip et al., 2017; Ligneul et al., 2021). Signal averaging over a longer time course
628 has been shown to smooth out any task-based dynamics of neural activity (Mangia et al., 2007;
629 Mullins, 2018) and brain homeostasis during long stimulation blocks might lead to dismissal of, or
630 minimal, metabolic changes (Mangia et al., 2012; Apšvalka et al., 2015).

631 These limitations can be overcome by time-locking fMRS to stimulus onset and assessing
632 metabolic changes with higher temporal resolution. The temporal resolution of the event-related
633 approach can be brought to under 30 seconds or less, allowing for measurement of a relatively
634 fast response at the cost of increased measurement uncertainty of the individual time point due
635 to decreased SNR. Several approaches have been implemented to successfully improve temporal
636 resolution without sacrificing SNR, including sliding window, and/or averaging over participants,
637 which will be discussed further in Section 3.1.

638 It is likely that the optimal choice of paradigm depends on the targeted stimulus domain.
639 Any study with “long term” change (i.e., learning, memory, or even pharmacological approaches)
640 may consider using block paradigms as these hold an advantage of higher SNR (Jahng et al., 2016;
641 Bezalel et al., 2019; Vijayakumari et al., 2020). As previously discussed, block design often involves
642 repeat stimulation with the theorised summation brain response, while event-related designs with
643 fewer transients are likely to elicit a smaller response, which, even when averaged together, is not
644 driven by repeated summation of stimuli. While this is not the right approach to assess transient
645 responses, when someone is interested in more long-term changes, both our data and prior work
646 suggests block designs may be more robust (Jahng et al., 2016; Bezalel et al., 2019; Vijayakumari
647 et al., 2020). While this is speculative, our meta-analysis based on available data showed that block

648 designs tend to have higher effect sizes than event-related designs. Nevertheless, careful fMRS
649 paradigm design might allow for investigation of both block and event-related analysis within the
650 same acquisition (Apšvalka et al., 2015; Stanley et al., 2017; Woodcock et al., 2018) through careful
651 study design, but this is not widely used.

652

653 2.2 Effect of stimulus domain

654 The directions and magnitudes of metabolic changes are influenced by stimulus domain. A
655 significant increase compared to baseline was observed for Glu/Glx in five domains (exercise,
656 learning, motor, stress, tDCs). Increased Glu/Glx during stimulation is in line with studies showing
657 that neuronal responses require increased energy metabolism and/or excitatory
658 neurotransmission. Although effect sizes were small, GABA concentrations tended to decrease in
659 response to stimulation, except for %change in the motor domain. This is in agreement with
660 previous studies demonstrating a negative relationship between regional neural activation and
661 GABA, and a deactivation of GABAergic mechanisms when excitation is required (Duncan et al.,
662 2014; Kiemes et al., 2021). It has been suggested that task-related GABA changes are more
663 robustly observed in stimulus paradigms with a change in behavioural performance (Ip and Bridge,
664 2021), such as learning (Frangou et al., 2018, 2019), motor or sensory performance (Stagg et al.,
665 2011; Heba et al., 2016; Kolasinski et al., 2019), and stress (Houtepen et al., 2017; Lynn et al.,
666 2018a); this is reflected in our meta-analysis results, and GABA changes do not appear particularly
667 robust. fMRS studies in pain appeared to be most consistent, but most domains show huge
668 variation in their responses. GABA changes tend to be moderate at best and appear very domain-
669 and approach, specific.

670 The high I^2 across stimulus domains observed in this meta-analysis reflects the high degree
671 of heterogeneity in results for different paradigms and stimuli even within stimulus domain. While
672 we expected some variation as stimulus parameters and stimulation approach will differ between
673 studies, we were surprised by this large heterogeneity. It should be noted that classification of
674 stimulation domains may vary depending on individual opinion and judgement. For example, we
675 grouped all visual stimulation fMRS studies into one category, despite differences in experimental

676 design, stimulus intensity, and stimulus duration, which likely influenced the observed results
677 (Mullins, 2018; Stanley and Raz, 2018; Ip and Bridge, 2021). Especially in the visual domain, we
678 found a lot of heterogeneity, likely due to the variety in visual tasks including flashing checker
679 boards with different flickering frequency, movie or clip-videos as visual stimulus, rotating
680 checkerboard, and visual stimulations with variations in contrast level (Mangia et al., 2012; Kim et
681 al., 2013b, 2014; Betina Ip et al., 2017; Mekle et al., 2017; Bednářík et al., 2018; Martínez-Maestro
682 et al., 2019). Previous studies demonstrated regional cerebral blood flow change in linear function
683 with stimulus repetition rates that peaked at approximately 8 Hz then decline above this frequency
684 (Fox and Raichle, 1984; Bejm et al., 2019). Previous fMRI studies also reported BOLD response to
685 be depends on stimulus patterns (Krüger et al., 1998; Hoge et al., 1999). Similarly, perhaps
686 approaches with higher SNR (such as 7T) are more sensitive to changes (Mangia et al., 2012).

687 Combining visual stimulus studies was necessary, however, as separating them out further
688 would lead to single study analysis, which is not particularly useful for meta-analytical purposes.
689 However, we do know stimulus parameters can have different effects. Previous studies have
690 demonstrated a lack of both Glu and BOLD signal changes at low visual contrast level, whereas
691 only high stimulus intensity elicited a measurable and significant Glu response (Ip et al., 2019). This
692 suggests that stimuli used for fMRS are preferably ones with high-intensity to evoke a sufficiently
693 salient response (e.g., in a considerable number of neurons) to cause neurometabolite production
694 or spillover (Yashiro et al., 2005; Gonçalves-Ribeiro et al., 2019), which leads to a measurable
695 transient change that can be measured with MRS. Additionally, MRS-derived neurometabolite
696 signals are non-specific and reflect all cellular component (e.g., cytosol, extracellular space, vesicle,
697 synaptic cleft, etc.). It is possible that a smaller brain response with less SNR (e.g., one induced by
698 repetitive stimulation) could be masked by other metabolic responses with higher SNR (e.g.,
699 energy usage, steady state).

700 2.3 Effect of ROI

701 Although we intended to study the effect of ROI on effect size, there was insufficient data
702 to draw firm conclusions. Despite the occipital ROI being the most studied ROI in fMRS (and MRS
703 in general, (Puts and Edden, 2012)), and with the benefit of high-quality spectra due to its

704 homogenous field relative to other ROIs (Juchem and de Graaf, 2017), only %change_{Glu/Glx} was
705 significantly increased compared to baseline. A significant *increase* of GABA was demonstrated for
706 frontal and parietal ROIs which included fMRS studies of visual, exercise, motor, stress and learning
707 stimulus; all these involved some kind of repeated stimulation and likely to reflect plasticity. This
708 is consistent with the notion that both frontal and parietal regions play important roles in
709 regulating inhibitory control of behaviour (Aron et al., 2004; Narayanan and Laubach, 2017;
710 Hermans et al., 2018). An increase in Glu/Glx was demonstrated for insular cortex and other
711 temporal lobe regions. While we can only speculate why this appears to be more robust t, it might
712 be that there is less variation in the approach used for insular regions compared to other regions,
713 for example, visual studies. It is possible that paradigms targeting insular/parietal regions elicit
714 stronger responses in these regions than visual stimuli do in visual regions, but it might also be the
715 case that voxels have less heterogeneity (as heterogeneity even within occipital lobe is large, and
716 different occipital regions have very different roles).

717 The differences in both of direction and magnitude due to anatomical differences and
718 functional differences of ROIs are not surprising (Gordon et al., 2017; Zhang et al., 2020). Different
719 brain regions typically contain different tissue compositions (i.e., white and grey matter) (Pouwels
720 and Frahm, 1998; Amaral et al., 2013). Differences in tissue composition also leads to variation
721 in metabolism with grey matter having higher energy consumption compared to white matter
722 (Amaral et al., 2013; Ford and Crewther, 2016), which in turn, affects GABA, Glu and Glx levels
723 (Rae et al., 2009; Rae, 2014) *and see also next section*. We were not able to determine the role of
724 tissue composition and subsequent partial volume correction, which accounts for much variation
725 in the estimation of GABA and Glx/Glu, due to limited available and reported data. Another
726 possible explanation for differences in effect sizes between ROIs could arises from increase SNR in
727 certain regions (e.g., occipital lobe) with close proximity to the receiver coil as well (Di Costanzo et
728 al., 2007; Minati et al., 2010). Nevertheless, further primary studies are required to further
729 elucidate the relationship between effect sizes and brain region.

730

731 **2.4 Possible mechanisms underly metabolite changes**

732 While directional changes in the neurometabolite responses were observed in this meta-
733 analysis, the mechanisms underlying these changes remain unclear. Metabolite concentrations
734 obtained in fMRS studies originate from all cell compartments (i.e., cell body, cytosol, synaptic
735 cleft, etc.) (Puts and Edden, 2012). The brain's response to external stimuli consists of a complex
736 interplay between neuronal mechanisms. This includes changes in blood flow, changes in
737 neurotransmitter transport, production and breakdown, and brain oxidative metabolism (Fox and
738 Raichle, 2007; Mangia et al., 2009; Takado et al., 2021). Besides neuronal synaptic activity,
739 metabolic processes also contribute to the neurometabolite levels measured in MRS (e.g., the TCA
740 cycle)(Dienel, 2012; Magistretti and Allaman, 2015).

741 Our finding of increased Glu/Glx during stimulation/tasks is in agreement with several
742 studies that link Glu and brain responses to stimulus such as perception, visual activation, motor
743 activation, learning, and memory (Gao et al., 2013; Magalhães et al., 2019; Ligneul et al., 2021).
744 Glu plays a major role during activity-dependent energy demands as the most abundant amino-
745 acid and the main excitatory neurotransmitter in the brain (Ligneul et al., 2021). Increasing
746 evidence demonstrates the close regulation between glucose consumption and glutamate-
747 glutamine cycling (Sibson et al., 1998; Rothman et al., 2003), which was theorised to lead to
748 increasing Glu levels during the BOLD-activation period (Betina Ip et al., 2017; Vijayakumari et al.,
749 2018; Martínez-Maestro et al., 2019). Additionally, Glu is also a major determinant for neuronal
750 plasticity during periods of high neural activity as Glu influence the production of of brain-derived
751 neurotrophic factor (BDNF) which regulates survival, differentiation and synaptogenesis in the CNS
752 to change patterns of neuronal connectivity (Gonçalves-Ribeiro et al., 2019; Valtcheva and
753 Venanc, 2019). Indeed, Glu release by neurons and its uptake to astrocytes for recycling via
754 glutamine is thought to represent 70-80% of total brain glucose consumption (Hertz and Rothman,
755 2016). That said, it is not possible to differentiate metabolic Glu from vesicular or synaptic Glu,
756 and caution in the interpretation of Glu/Glx changes is important; one cannot simply extrapolate
757 these changes to changes in neurotransmission.

758 Previous studies have demonstrated the relationship between GABA as measured with MRS
759 and the gene encoding for glutamic acid decarboxylase (GAD) 67. GAD 67 is responsible for
760 converting Glu into GABA under baseline conditions and the majority of GABA production, and is

761 present in both cell bodies (Marenco et al., 2010) and synapses. Therefore, MRS quantified GABA
762 is often said to reflect 'inhibitory tone' (Rae, 2014; Peek et al., 2020). The relationship between
763 GABA and neuronal activation (or deactivation) is less consistent, and often dependent on the task
764 used. Previous work has shown that increased GABA levels are associated with increased BOLD
765 signal in response to an interference task (Kühn et al., 2016) and in response to pharmacological
766 manipulation in rat brain (Chen et al., 2005). However, other studies have shown that higher
767 baseline GABA was associated with lower BOLD response amplitude (Muthukumaraswamy et al.,
768 2012; Rae, 2014; Stanley and Raz, 2018). It has been suggested that Glu/Glx and GABA changes in
769 response to stimulation comprise of both energy usage and neural process facilitating a shift into
770 new metabolic steady-state by shifting the excitation/inhibition equilibrium, linking these two
771 processes more directly (Just et al., 2013; Lynn et al., 2018b). A recent fMRS study in animals
772 models showed that increases in GABA after repeated tactile stimulation were consistent with
773 two-photon microscopy measures of increased inhibitory activity, and increases in Glu with
774 increased excitatory activity, suggesting that functional changes in GABA and Glu measured
775 through MRS are indeed reflective of increased inhibitory neurotransmission (Takado et al., 2021).

776

777 3. Effect of fMRS parameters

778 Beyond assessing fMRS through differences and changes in the 'bulk' metabolite response
779 to stimulation, it is also important to investigate differences at the level of acquisition and analysis.
780 In this meta-analysis, we demonstrated the effect of MRS parameters such as number of
781 transients, voxel size, timing, and MRS quality limitations on reported metabolite concentrations.

782

783 3.1 Number of transients

784 The results reported in our meta-analysis illustrate the variability of methods used in fMRS
785 studies. For both Glu/Glx and GABA, effect sizes seem to be higher for a lower number of
786 transients, and effect size decreases as the number of transients increase. There are several
787 possible explanations for this; One is that low transient sizes lead to lower SNR and unreliable

788 spectral quantification (Mikkelsen et al., 2018), which potentially lead to biased metabolite
789 concentration changes. Another possible explanation is that rapid changes in the first few minutes
790 due to neurotransmitter release might influence the effect sizes observed with a small number of
791 transients due to their higher temporal resolution (Mullins, 2018; Ligneul et al., 2021). On the
792 other hand, a larger number of transients might lead to lower effect size observed due the effect
793 being averaged out over a longer period of time (Ip and Bridge, 2021), thus diluting any rapid
794 changes. Ultimately, conclusions are difficult to draw without a measurable ground truth, since
795 the spectral fitting process itself may introduce quantitative bias depending on SNR (and therefore
796 the width of the averaging window). Synthetic simulated data can be useful to elucidate the
797 accuracy, precision, and biases of spectral fitting when attempting to resolve small temporal
798 changes.

799 Given the approximate 10^4 times lower metabolite concentrations relative to water, and
800 thus low SNR, spectra are often collected with long acquisition times. These acquisition times are
801 often longer than the assumed temporal dynamics with fast metabolite changes in less than 1s
802 (Apšvalka et al., 2015; Bednářík et al., 2015; Mullins, 2018; Ligneul et al., 2021) which likely reflect
803 changes in visibility in existing metabolite pools. Several spectral averaging methods have been
804 applied to overcome this trade-off between temporal resolution and SNR (Kanowski et al., 2004;
805 Mikkelsen et al., 2018). One of these averaging methods included averages fMRS data across short
806 sequential acquisition blocks (Kolasinski et al., 2019). Others used time-locking to stimulus onset
807 followed by averaged transients acquired during stimulus presentation or baseline, comparing the
808 two, as event-related averaging (Lally et al., 2014 p.201; Apšvalka et al., 2015; Stanley et al., 2017).
809 Some studies have averaged across a small number of transients but across participants to obtain
810 group-level spectra with higher temporal resolution (Apšvalka et al., 2015; Bednářík et al., 2015;
811 Fernandes et al., 2020). Others have applied a ‘sliding window’ or ‘moving averages’ approach (i.e.,
812 average transients in blocks then shifting the averaging over time by a certain transient window
813 width) to detect a dynamic trace of metabolite changes (Mangia et al., 2007; Schaller et al., 2013;
814 Fernandes et al., 2020; Rideaux, 2020).

815 Our results are in agreement with studies suggesting averaging across a small number of
816 transients has an advantage of higher temporal resolution for detecting rapid modulation of

817 metabolite levels (Lally et al., 2014; Betina Ip et al., 2017; Ligneul et al., 2021). A longer averaging
818 window might be better associated with moving towards a new steady metabolism as described
819 above (Betina Ip et al., 2017; Lynn et al., 2018a). Furthermore, the brain likely responds differently
820 to different types of stimuli, and in a region-specific manner, once again emphasising that task
821 design needs to be tailored towards the question of interest. Surprisingly, we know very little
822 about the actual temporal dynamics of these metabolites thus makes it difficult to a priori choose
823 the best acquisition strategy. Only a few studies were included to allow for the consideration of
824 the impact of transient width, which supports the urgent needs in of more primary studies of fMRS
825 with varying time windows.

826

827 3.2 fMRS timing

828 Our analysis allowed us to explore whether effect sizes change with time of acquisition.
829 While exploratory, these time-resolved fluctuation patterns suggest different response functions
830 for different brain regions or stimulus domains, *and* between GABA and Glu/Glx. Some studies
831 observed a fast Glu response early in a working memory task, but not later in the task (Woodcock
832 et al., 2018), while others observed Glu reaching a new steady state 1 to 2 minutes after stimulus
833 onset (Mangia et al., 2007; Schaller et al., 2013). Previous studies of GABA and Glx in response to
834 visual stimulation demonstrated concentration drifts over time in opposite directions while
835 participants were at 'rest' before stabilising (in steady state) after around 500 seconds (Rideaux,
836 2020). As discussed in previous sections, the time courses of neurometabolites in response to
837 stimulus domain are a topic of great interest and require further elucidation. This perhaps can be
838 achieved by varying the time of fMRS acquisition and stimulus onset in high-field MR at > 3 T, while
839 aiming for the best temporal resolution possible.

840

841 3.3 Others MR-instrument-related limitations

842 fMRS is also sensitive to other instrument and acquisition-related limitations. MRS offers
843 low spatial specificity as large voxels (often >15 ml) are required for sufficient SNR. Reducing voxel

844 size requires increasing acquisition time to maintain SNR, which is not only impractical, but also
845 increases the risk of scanner drift and participant motion, especially in clinically sensitive motion-
846 prone groups such as prenatal and people with neurodevelopmental conditions (Mikkelsen et al.,
847 2018; Hui et al., 2021; Ip and Bridge, 2021).

848

849 **4. Quality assurance of MRS**

850 Differences in fMRS parameters go hand-in-hand with quality assurance. There is no
851 consensus on minimally best practice for fMRS to date. Currently available quality assurance and
852 reporting metrics (MRS-Q and MRSinMRS) were designed for static MRS (Peek et al., 2020; Lin et
853 al., 2021), and do not take into account functional approaches where the averaged number of
854 transients is often lower to achieve better temporal resolution. Notably, many studies reported
855 here used smaller voxel sizes compared to consensus recommendation (~27 ml for edited MRS for
856 GABA, 3 T, and ~3.4 ml for unedited at 128 transients, 3T) (Lin et al., 2021). Smaller voxel size
857 inconsistent with consensus standards was often observed in particular for spectral editing of
858 GABA, and findings may be less reliable due to insufficient SNR. Here, we used standard language
859 for quality assessment (such as high or low quality) but should of course note that this language
860 often refers to studies not reporting sufficient information. It is our hope that with the increasing
861 consensus in reporting, this will become less of a concern. We should also note that some studies
862 used “low quality” approaches compared to the consensus now but need to see these in a
863 historical perspective. Despite several studies reporting inadequate fMRS parameters, our
864 sensitivity analysis based on study quality shows no extreme changes from analyses including all
865 studies. While there is room for improvement for reporting of fMRS, most of the studies used
866 adequate fMRS scan parameters. It is possible that the number of transients is less important
867 when modelling time-course data and using within-participant designs. Establishing minimum
868 reporting standard in this early stage would greatly increase reproducibility in a field that offers
869 an almost unlimited number of data analysis strategies.

870

871 **5. Sources of bias**

872 As discussed in the previous sections, there are various sources of bias in fMRS study
873 design, acquisition, and analysis parameters (i.e., brain area, voxel size, number of transients, and
874 metabolite unit, e.g., percentage change or mean concentration). Study quality assessments
875 further suggest that fMRS studies lack randomisation and blinding of participants. Additional risk
876 of bias could arise from selection of participants, for example, studies often using colleagues as
877 participants for the study. fMRS studies such as stress or pharmacological designs often use a pre-
878 post within-participant design, this introduces bias into the analysis (Ma et al., 2020) and
879 potentially leads to reporting of positive results (publication bias) (Rosenthal, 1979; Murphy and
880 Aguinis, 2019). Additional sources of bias were beyond the scope of this meta-analysis. These
881 include the general experiment design, such as population sampling and type of baseline condition
882 such as difference type of visual baseline condition of eyes close or a fixation cross (Ip et al., 2019;
883 Ip and Bridge, 2021), the choice of analysis approach including differences between spectral
884 modelling algorithms (Zöllner et al., 2021, 2022; Craven et al., 2022; Marjańska et al., 2022),
885 quantification and referencing (metabolite in institutional units [IU], absolute concentration or
886 ratio to creatine [Cr], etc.)(Porges et al., 2017), and how results are reported (e.g., reported only
887 in percentage change but not in concentration). In particular, the choice of quantification
888 reference compound might have a strong impact, although it is assumed typical reference
889 compounds such as Cr or NAA are unlikely to change with stimulation (Wilson et al., 2019). One
890 important parameter that needs further investigation and consensus treatment is linewidth
891 adjustment based on the BOLD signal. Since haemoglobin is paramagnetic when deoxygenated,
892 but diamagnetic when oxygenated, local magnetic susceptibility depends on the blood-oxygen
893 level. BOLD activation causes narrowed MRS lines and increased signal magnitude that can lead to
894 overestimation of metabolite levels if uncorrected (Zhu and Chen, 2001; Betina Ip et al., 2017). In
895 the present study, we did not have sufficient information to perform an analysis on these topics.

896 As shown in the results, the type of data reported (mean or %change) influences the effect
897 sizes observed. Most fMRS studies reported results as %change, followed by ratio to reference
898 molecule (e.g., tCr, NAA). Our meta-analysis avoids the secondary calculation of data by analysing
899 data as presented. For the sake of transparency and understanding these impacts, we suggest
900 reporting data in both comparative result (e.g., %change, change from baseline) and in mean

901 metabolite concentration (e.g., ratio to reference metabolite, mmol/kg, institutional units) in the
902 future. These results often support and strengthen each other and increase comparability
903 between studies. Future study could investigate the Glu and GABA ratio as a theoretical index of
904 E/I balanced, although the exact relationship between MRS-derived Glu/GABA concentration and
905 E/I balanced is still under active debate (Steel et al., 2020; Rideaux, 2021).

906

907 **6. Limitation of the current meta-analysis**

908 Several limitations to this meta-analysis study need to be acknowledged when interpreting
909 this current work. While the data were considered based on data type (mean and %change), we
910 had to assume that the units included were on the same scale, and that reference metabolites
911 concentration (e.g., creatine or NAA) remained relatively unchanged (Steen et al., 2005; Rae,
912 2014). Another potential limitation is that we included all studies regardless of study quality as
913 assessed by both ROBANS and MRS-Q in our main meta-analysis. The sensitivity analysis of high-
914 quality studies according to MRS-Q suggested that the studies included showed interchangeable
915 results regardless of quality, and we recognize that the MRS-Q, while useful, does not fully apply
916 to functional MRS. While we aim to comprehensively include all fMRS studies to date,
917 unfortunately our search strategy may have missed out on more recent work, such as Ip et al.
918 (2019); we did not identify this paper through other means. Lastly, there was a lack of statistical
919 power for some stimulus domains and fMRS paradigm due to the small numbers of studies
920 included. Taken together, fMRS is a field with enormous possibility, but with several sources of
921 bias and variability that need to be addressed.

922 In this current study, we employed the RVE method to synthesize effect sizes for each
923 stimulus domain from the multiple outcomes available (i.e., multiple within-study outcomes).
924 While some significant changes from baseline were noted in some stimulus domains, often they
925 led to single-study meta-analyses with several datasets from various timepoints included (varying
926 from 3-9) in each single-study per each domain. These results therefore need to be interpreted
927 with care as there is study-bias.

928

929 7. Conclusion

930 We established effect sizes and directionality of the GABA, Glx and Glu response in all
931 currently available fMRS studies. Our results demonstrated relatively small effect sizes and large
932 heterogeneity, limiting the current state of fMRS as a technique in investigating neurodynamic
933 responses in the healthy brain. However, we attempt to address these limitations and hope that
934 advances in these approaches have promise for application in atypical brain function. fMRS of
935 clinical conditions is surprisingly under-studied, but holds promise for understanding a dynamic
936 system, with potential implications for drug response and diagnosis. As such, fMRS holds great
937 potential to be used alongside other techniques to perturb GABA and Glutamate mechanisms,
938 including TMS and pharmacological challenges and assess the impact on the system in both typical
939 and atypical brain. Furthermore, combining fMRS with other imaging techniques, such as EEG or
940 fMRI, allows for associating (f)MRS with distinct neural mechanisms associated with E/I balance.

941 This meta-analysis highlights the urgent need for consensus for standardised reporting and
942 minimal best practices to improve the reproducibility of fMRS. Additionally, there remains a lack
943 of fundamental knowledge of fMRS, for example, with respect to metabolic time courses.
944 Establishing fMRS paradigms and parameters that evoke metabolic responses with high reliability
945 and reproducibility would be of great interest in this early state of the field as it would allow for
946 measuring atypical responses more readily, and ultimately lead to elucidation of underlying
947 mechanisms of brain function in both health and disease.

948

949

950 **References**

951 Amaral A, Meisingset T, Kotter M, Sonnewald U (2013) Metabolic Aspects of Neuron-Oligodendrocyte-
952 Astrocyte Interactions. *Frontiers in Endocrinology* 4 Available at:
953 <https://www.frontiersin.org/article/10.3389/fendo.2013.00054> [Accessed January 25, 2022].

954 Ankit Rohatgi (2021) WebPlotDigitizer. Available at: <https://automeris.io/WebPlotDigitizer>.

955 Apšvalka D, Gadie A, Clemence M, Mullins PG (2015) Event-related dynamics of glutamate and BOLD
956 effects measured using functional magnetic resonance spectroscopy (fMRS) at 3T in a repetition
957 suppression paradigm. *NeuroImage* 118:292–300.

958 Archibald J, MacMillan EL, Graf C, Kozlowski P, Laule C, Kramer JLK (2020) Metabolite activity in the
959 anterior cingulate cortex during a painful stimulus using functional MRS. *Scientific reports*
960 10:19218–19218.

961 Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. *Trends in
962 Cognitive Sciences* 8:170–177.

963 Baeshen A, Wyss PO, Henning A, O’Gorman RL, Piccirelli M, Kollias S, Michels L (2020) Test–Retest
964 Reliability of the Brain Metabolites GABA and Glx With JPRESS, PRESS, and MEGA-PRESS MRS
965 Sequences in vivo at 3T. *Journal of Magnetic Resonance Imaging* 51:1181–1191.

966 Baslow MH, Cain CK, Sears R, Wilson DA, Bachman A, Gerum S, Guilfoyle DN (2016) Stimulation-induced
967 transient changes in neuronal activity, blood flow and N-acetylaspartate content in rat prefrontal
968 cortex: a chemogenetic fMRS-BOLD study. *NMR in Biomedicine* 29:1678–1687.

969 Bednářík P, Tkáč I, Giove F, DiNuzzo M, Deelchand DK, Emir UE, Eberly LE, Mangia S (2015) Neurochemical
970 and BOLD responses during neuronal activation measured in the human visual cortex at 7 Tesla.
971 *Journal of cerebral blood flow and metabolism : official journal of the International Society of
972 Cerebral Blood Flow and Metabolism* 35:601–610.

973 Bednářík P, Tkáč I, Giove F, Eberly LE, Deelchand DK, Barreto FR, Mangia S (2018) Neurochemical
974 responses to chromatic and achromatic stimuli in the human visual cortex. *J Cereb Blood Flow
975 Metab* 38:347–359.

976 Begg CB, Mazumdar M (1994) Operating Characteristics of a Rank Correlation Test for Publication Bias.
977 *Biometrics* 50:1088–1101.

978 Bejm K, Wojtkiewicz S, Sawosz P, Perdziak M, Pastuszak Z, Sudakou A, Guchek P, Liebert A (2019)
979 Influence of contrast-reversing frequency on the amplitude and spatial distribution of visual
980 cortex hemodynamic responses. *Biomed Opt Express* 10:6296–6312.

981 Betina Ip I, Berrington A, Hess AT, Parker AJ, Emir UE, Bridge H (2017) Combined fMRI-MRS acquires
982 simultaneous glutamate and BOLD-fMRI signals in the human brain. *NeuroImage* 155:113–119.

983 Bezalel V, Paz R, Tal A (2019) Inhibitory and excitatory mechanisms in the human cingulate-cortex support
984 reinforcement learning: A functional Proton Magnetic Resonance Spectroscopy study.
985 *NeuroImage* 184:25–35.

986 Boillat Y, Xin L, van der Zwaag W, Gruetter R (2020) Metabolite concentration changes associated with
987 positive and negative BOLD responses in the human visual cortex: A functional MRS study at 7
988 Tesla. *Journal of cerebral blood flow and metabolism : official journal of the International Society*
989 of Cerebral Blood Flow and Metabolism 40:488–500.

990 Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2021) Introduction to meta-analysis. John Wiley &
991 Sons.

992 Bottomley PA (1984) Selective volume method for performing localized NMR spectroscopy. Google
993 Patents.

994 Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. *Annals of the New York Academy of*
995 *Sciences* 508:333–348.

996 Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments: effect
997 estimation and bias detection through Egger regression. *International journal of epidemiology*
998 44:512–525.

999 Cai K, Nanga RP, Lamprou L, Schinstine C, Elliott M, Hariharan H, Reddy R, Epperson CN (2012) The Impact
1000 of Gabapentin Administration on Brain GABA and Glutamate Concentrations: A 7T 1H-MRS Study.
1001 *Neuropsychopharmacol* 37:2764–2771.

1002 Chen C, Sigurdsson HP, Pépés SE, Auer DP, Morris PG, Morgan PS, Gowland PA, Jackson SR (2017)
1003 Activation induced changes in GABA: Functional MRS at 7T with MEGA-sLASER. *NeuroImage*
1004 156:207–213.

1005 Chen W, Novotny EJ, Zhu XH, Rothman DL, Shulman RG (1993) Localized 1H NMR measurement of
1006 glucose consumption in the human brain during visual stimulation. *Proc Natl Acad Sci U S A*
1007 90:9896–9900.

1008 Chen Z, Silva AC, Yang J, Shen J (2005) Elevated endogenous GABA level correlates with decreased fMRI
1009 signals in the rat brain during acute inhibition of GABA transaminase. *J Neurosci Res* 79:383–391.

1010 Chiappelli J, Shi Q, Wijtenburg SA, Quiton R, Wisner K, Gaston F, Kodi P, Gaudiot C, Kochunov P, Rowland
1011 LM, Hong LE (2018) Glutamatergic Response to Heat Pain Stress in Schizophrenia. *Schizophr Bull*
1012 44:886–895.

1013 Cleve M, Gussew A, Reichenbach JR (2015) In vivo detection of acute pain-induced changes of GABA+ and
1014 Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. *NeuroImage*
1015 105:67–75.

1016 Cleve M, Gussew A, Wagner G, Bär K-J, Reichenbach JR (2017) Assessment of intra- and inter-regional
1017 interrelations between GABA+, Glx and BOLD during pain perception in the human brain - A
1018 combined (1)H fMRS and fMRI study. *Neuroscience* 365:125–136.

1019 Coglan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ (2012) GABA system dysfunction in
1020 autism and related disorders: from synapse to symptoms. *Neurosci Biobehav Rev* 36:2044–2055.

1021 Coxon JP, Cash RFH, Hendrikse JJ, Rogasch NC, Stavrinos E, Suo C, Yücel M (2018) GABA concentration in
1022 sensorimotor cortex following high-intensity exercise and relationship to lactate levels. *The
1023 Journal of Physiology* 596:691–702.

1024 Craven AR, Bhattacharyya PK, Clarke WT, Dydak U, Edden RAE, Ersland L, Mandal PK, Mikkelsen M,
1025 Murdoch JB, Near J, Rideaux R, Shukla D, Wang M, Wilson M, Zöllner HJ, Hugdahl K, Oeltzschnner
1026 G (2022) Comparison of seven modelling algorithms for γ -aminobutyric acid-edited proton
1027 magnetic resonance spectroscopy. *NMR in Biomedicine* 35 Available at:
1028 <https://onlinelibrary.wiley.com/doi/10.1002/nbm.4702> [Accessed August 26, 2022].

1029 Deelchand DK, Marjańska M, Henry P-G, Terpstra M (2021) MEGA-PRESS of GABA+: Influences of
1030 acquisition parameters. *NMR in Biomedicine* 34:e4199.

1031 Dennis A, Thomas AG, Rawlings NB, Near J, Nichols TE, Clare S, Johansen-Berg H, Stagg CJ (2015) An Ultra-
1032 High Field Magnetic Resonance Spectroscopy Study of Post Exercise Lactate, Glutamate and
1033 Glutamine Change in the Human Brain. *Front Physiol* 6 Available at:
1034 <https://www.frontiersin.org/articles/10.3389/fphys.2015.00351/full> [Accessed June 20, 2021].

1035 Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, Scarabino T (2007) Proton MR
1036 spectroscopy of the brain at 3 T: an update. *Eur Radiol* 17:1651–1662.

1037 Dienel GA (2012) Brain Lactate Metabolism: The Discoveries and the Controversies. *J Cereb Blood Flow
1038 Metab* 32:1107–1138.

1039 Donahue MJ, Near J, Blicher JU, Jezzard P (2010) Baseline GABA concentration and fMRI response.
1040 *Neuroimage* 53:392–398.

1041 Duarte JMN, Lei H, Mlynárik V, Gruetter R (2012) The neurochemical profile quantified by in vivo 1H NMR
1042 spectroscopy. *NeuroImage* 61:342–362.

1043 Duncan NW, Wiebking C, Northoff G (2014) Associations of regional GABA and glutamate with intrinsic
1044 and extrinsic neural activity in humans—A review of multimodal imaging studies. *Neuroscience &
1045 Biobehavioral Reviews* 47:36–52.

1046 Duval S, Tweedie R (2000) A nonparametric “trim and fill” method of accounting for publication bias in
1047 meta-analysis. *Journal of the american statistical association* 95:89–98.

1048 Dwyer GE, Craven AR, Bereśniewicz J, Kazimierczak K, Ersland L, Hugdahl K, Grüner R (2021) Simultaneous
1049 Measurement of the BOLD Effect and Metabolic Changes in Response to Visual Stimulation Using
1050 the MEGA-PRESS Sequence at 3 T. *Frontiers in Human Neuroscience* 15 Available at:
1051 <https://www.frontiersin.org/article/10.3389/fnhum.2021.644079>.

1052 Edden RAE, Barker PB (2007) Spatial effects in the detection of gamma-aminobutyric acid: improved
1053 sensitivity at high fields using inner volume saturation. *Magn Reson Med* 58:1276–1282.

1054 Edden RAE, Muthukumaraswamy SD, Freeman TCA, Singh KD (2009) Orientation Discrimination
1055 Performance Is Predicted by GABA Concentration and Gamma Oscillation Frequency in Human
1056 Primary Visual Cortex. *J Neurosci* 29:15721–15726.

1057 Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical
1058 test. *BMJ* 315:629–634.

1059 Faghihi R, Zeinali-Rafsanjani B, Mosleh-Shirazi M-A, Saeedi-Moghadam M, Lotfi M, Jalli R, Iravani V (2017)
1060 Magnetic Resonance Spectroscopy and its Clinical Applications: A Review. *J Med Imaging Radiat*
1061 *Sci* 48:233–253.

1062 Ferguson BR, Gao W-J (2018) PV Interneurons: Critical Regulators of E/I Balance for Prefrontal Cortex-
1063 Dependent Behavior and Psychiatric Disorders. *Frontiers in Neural Circuits* 12 Available at:
1064 <https://www.frontiersin.org/articles/10.3389/fncir.2018.00037> [Accessed October 8, 2022].

1065 Fernandes CC, Lanz B, Chen C, Morris PG (2020) Measurement of brain lactate during visual stimulation
1066 using a long TE semi-LASER sequence at 7 T. *NMR in biomedicine* 33:e4223–e4223.

1067 Floyer-Lea A, Wylezinska M, Kincses T, Matthews PM (2006) Rapid Modulation of GABA Concentration in
1068 Human Sensorimotor Cortex During Motor Learning. *Journal of Neurophysiology* 95:1639–1644.

1069 Ford TC, Crewther DP (2016) A Comprehensive Review of the 1H-MRS Metabolite Spectrum in Autism
1070 Spectrum Disorder. *Frontiers in Molecular Neuroscience* 9 Available at:
1071 <https://www.frontiersin.org/article/10.3389/fnmol.2016.00014> [Accessed January 25, 2022].

1072 Fox MD, Raichle ME (2007) Spontaneous fluctuations in brain activity observed with functional magnetic
1073 resonance imaging. *Nat Rev Neurosci* 8:700–711.

1074 Fox PT, Raichle ME (1984) Stimulus rate dependence of regional cerebral blood flow in human striate
1075 cortex, demonstrated by positron emission tomography. *Journal of Neurophysiology* 51:1109–
1076 1120.

1077 Frahm J al, Bruhn H, Gyngell M, Merboldt K, Hänicke W, Sauter R (1989) Localized high-resolution proton
1078 NMR spectroscopy using stimulated echoes: initial applications to human brain *in vivo*. *Magnetic*
1079 *resonance in medicine* 9:79–93.

1080 Frangou P, Correia M, Kourtzi Z (2018) GABA, not BOLD, reveals dissociable learning-dependent plasticity
1081 mechanisms in the human brain King AJ, Silver M, Dosher BA, Greenhouse I, Silver M, eds. *eLife*
1082 7:e35854.

1083 Frangou P, Emir UE, Karlaftis VM, Nettekoven C, Hinson EL, Larcombe S, Bridge H, Stagg CJ, Kourtzi Z
1084 (2019) Learning to optimize perceptual decisions through suppressive interactions in the human
1085 brain. *Nat Commun* 10:474.

1086 Frank SM, Forster L, Pawellek M, Malloni WM, Ahn S, Tse PU, Greenlee MW (2021) Visual attention
1087 modulates glutamate-glutamine levels in vestibular cortex: Evidence from magnetic resonance
1088 spectroscopy. *The Journal of neuroscience : the official journal of the Society for Neuroscience*.

1089 Furlan AD, Pennick V, Bombardier C, van Tulder M, Group from the EB of the CBR (2009) 2009 Updated
1090 Method Guidelines for Systematic Reviews in the Cochrane Back Review Group. *Spine* 34:1929–
1091 1941.

1092 Gao F, Edden RA, Li M, Puts NA, Wang G, Liu C, Zhao B, Wang H, Bai X, Zhao C (2013) Edited magnetic
1093 resonance spectroscopy detects an age-related decline in brain GABA levels. *Neuroimage* 78:75–
1094 82.

1095 Gonçalves-Ribeiro J, Pina CC, Sebastião AM, Vaz SH (2019) Glutamate Transporters in Hippocampal
1096 LTD/LTP: Not Just Prevention of Excitotoxicity. *Frontiers in Cellular Neuroscience* 13:357.

1097 Gordon EM et al. (2017) Precision Functional Mapping of Individual Human Brains. *Neuron* 95:791–
1098 807.e7.

1099 Grames EM, Stillman AN, Tingley MW, Elphick CS (2019) An automated approach to identifying search
1100 terms for systematic reviews using keyword co-occurrence networks. *Methods in Ecology and*
1101 *Evolution* 10:1645–1654.

1102 Gussew A, Rzanny R, Erdtel M, Scholle HC, Kaiser WA, Mentzel HJ, Reichenbach JR (2010) Time-resolved
1103 functional ¹H MR spectroscopic detection of glutamate concentration changes in the brain during
1104 acute heat pain stimulation. *NeuroImage* 49:1895–1902.

1105 Gutzeit A, Meier D, Froehlich JM, Hergan K, Kos S, V Weymarn C, Lutz K, Ettlin D, Binkert CA, Mutschler J,
1106 Sartoretti-Schefer S, Brügger M (2013) Differential NMR spectroscopy reactions of
1107 anterior/posterior and right/left insular subdivisions due to acute dental pain. *European radiology*
1108 23:450–460.

1109 Gutzeit A, Meier D, Meier ML, von Weymarn C, Ettlin DA, Graf N, Froehlich JM, Binkert CA, Brügger M
1110 (2011) Insula-specific responses induced by dental pain. A proton magnetic resonance
1111 spectroscopy study. *European radiology* 21:807–815.

1112 Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: An R package and Shiny app
1113 for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital
1114 transparency and Open Synthesis. *Campbell Systematic Reviews* 18:e1230.

1115 Hak T, Van Rhee H, Suurmond R (2016) How to interpret results of meta-analysis, (Version 1.0).
1116 Rotterdam, The Netherlands: Erasmus Rotterdam Institute of Management. Available at:
1117 www.erim.eur.nl/research-support/meta-essentials.

1118 Harris AD, Saleh MG, Edden RAE (2017) Edited ¹H magnetic resonance spectroscopy *in vivo*: Methods
1119 and metabolites. *Magn Reson Med* 77:1377–1389.

1120 Hasler G, van der Veen JW, Grillon C, Drevets WC, Shen J (2010) Effect of acute psychological stress on
1121 prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. *Am J*
1122 *Psychiatry* 167:1226–1231.

1123 Heba S, Puts NAJ, Kalisch T, Glaubitz B, Haag LM, Lenz M, Dinse HR, Edden RAE, Tegenthoff M, Schmidt-
1124 Wilcke T (2016) Local GABA Concentration Predicts Perceptual Improvements After Repetitive
1125 Sensory Stimulation in Humans. *Cerebral Cortex* 26:1295–1301.

1126 Henning A (2018) Proton and multinuclear magnetic resonance spectroscopy in the human brain at ultra-
1127 high field strength: A review. *NeuroImage* 168:181–198.

1128 Hermans L, Leunissen I, Pauwels L, Cuypers K, Peeters R, Puts NAJ, Edden RAE, Swinnen SP (2018) Brain
1129 GABA Levels Are Associated with Inhibitory Control Deficits in Older Adults. *J Neurosci* 38:7844–
1130 7851.

1131 Hertz L, Rothman DL (2016) Glucose, Lactate, β -Hydroxybutyrate, Acetate, GABA, and Succinate as
1132 Substrates for Synthesis of Glutamate and GABA in the Glutamine-Glutamate/GABA Cycle. *Adv
1133 Neurobiol* 13:9–42.

1134 Higgins JP (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated
1135 March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org.

1136 Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne
1137 JAC (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*
1138 343:d5928.

1139 Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ*
1140 327:557–560.

1141 Hoge RD, Atkinson J, Gill B, Crelier GR, Marrett S, Pike GB (1999) Stimulus-Dependent BOLD and Perfusion
1142 Dynamics in Human V1. *NeuroImage* 9:573–585.

1143 Horder J, Petrinovic MM, Mendez MA, Bruns A, Takumi T, Spooren W, Barker GJ, Künnecke B, Murphy DG
1144 (2018) Glutamate and GABA in autism spectrum disorder—a translational magnetic resonance
1145 spectroscopy study in man and rodent models. *Translational psychiatry* 8:1–11.

1146 Houtepen LC, Schür RR, Wijnen JP, Boer VO, Boks MPM, Kahn RS, Joëls M, Klomp DW, Vinkers CH (2017)
1147 Acute stress effects on GABA and glutamate levels in the prefrontal cortex: A 7T 1H magnetic
1148 resonance spectroscopy study. *NeuroImage: Clinical* 14:195–200.

1149 Huang Z, Davis HHIV, Yue Q, Wiebking C, Duncan NW, Zhang J, Wagner N-F, Wolff A, Northoff G (2015)
1150 Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental
1151 imagery: A combined functional mrs and fMRI study. *Human brain mapping* 36:3204–3212.

1152 Hui SCN et al. (2021) Frequency drift in MR spectroscopy at 3T. *NeuroImage* 241:118430.

1153 IntHout J, Ioannidis JP, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects
1154 meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird
1155 method. *BMC Medical Research Methodology* 14:25.

1156 Ioannidis JPA, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-
1157 analyses: a large survey. *CMAJ* 176:1091–1096.

1158 Ip IB, Bridge H (2021) Investigating the neurochemistry of the human visual system using magnetic
1159 resonance spectroscopy. *Brain Struct Funct* Available at: <https://doi.org/10.1007/s00429-021-02273-0> [Accessed November 2, 2021].

1161 Ip IB, Emir UE, Parker AJ, Campbell J, Bridge H (2019) Comparison of Neurochemical and BOLD Signal
1162 Contrast Response Functions in the Human Visual Cortex. *J Neurosci* 39:7968–7975.

1163 Jahng G-H, Oh J, Lee D-W, Kim H-G, Rhee HY, Shin W, Paik J-W, Lee KM, Park S, Choe B-Y, Ryu C-W (2016)
1164 Glutamine and Glutamate Complex, as Measured by Functional Magnetic Resonance
1165 Spectroscopy, Alters During Face-Name Association Task in Patients with Mild Cognitive
1166 Impairment and Alzheimer's Disease. *Journal of Alzheimer's Disease* 52:145–159.

1167 Jelen LA, King S, Horne CM, Lythgoe DJ, Young AH, Stone JM (2019) Functional magnetic resonance
1168 spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics
1169 in the anterior cingulate cortex during a working memory task. *European*
1170 *neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*
1171 29:222–234.

1172 Jo S et al. (2014) GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.
1173 *Nat Med* 20:886–896.

1174 Juchem C, de Graaf RA (2017) B0 magnetic field homogeneity and shimming for in vivo magnetic
1175 resonance spectroscopy. *Anal Biochem* 529:17–29.

1176 Just N, Faber C (2019) Probing activation-induced neurochemical changes using optogenetics combined
1177 with functional magnetic resonance spectroscopy: a feasibility study in the rat primary
1178 somatosensory cortex. *Journal of Neurochemistry* 150:402–419.

1179 Just N, Sonnay S (2017) Investigating the Role of Glutamate and GABA in the Modulation of Transthalamic
1180 Activity: A Combined fMRI-fMRS Study. *Front Physiol* 8:30.

1181 Just N, Xin L, Frenkel H, Gruetter R (2013) Characterization of sustained BOLD activation in the rat barrel
1182 cortex and neurochemical consequences. *Neuroimage* 74:343–351.

1183 Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C (2004) Quantitation of simulated short
1184 echo time 1H human brain spectra by LCModel and AMARES. *Magnetic Resonance in Medicine*
1185 51:904–912.

1186 Kiemes A, Davies C, Kempton MJ, Lukow PB, Bennallick C, Stone JM, Modinos G (2021) GABA, Glutamate
1187 and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal 1H-MRS-fMRI
1188 Studies. *Frontiers in Psychiatry* 12:255.

1189 Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, Jang B-H, Son H-J (2013a) Testing a tool for assessing
1190 the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J*
1191 *Clin Epidemiol* 66:408–414.

1192 Kim T-H, Kang H-K, Jeong G-W (2013b) Assessment of brain metabolites change during visual sexual
1193 stimulation in healthy women using functional MR spectroscopy. *The journal of sexual medicine*
1194 10:1001–1011.

1195 Kim T-H, Kang H-K, Park K, Jeong G-W (2014) Localized brain metabolite changes during visual sexual
1196 stimulation in postmenopausal women: a pilot study using functional magnetic resonance
1197 spectroscopy. *Menopause (New York, NY)* 21:59–66.

1198 Klose U (2008) Measurement sequences for single voxel proton MR spectroscopy. *European journal of*
1199 *radiology* 67:194–201.

1200 Kolasinski J, Hinson EL, Zand APPD, Rizov A, Emir UE, Stagg CJ (2019) The dynamics of cortical GABA in
1201 human motor learning. *The Journal of Physiology* 597:271–282.

1202 Koush Y, de Graaf RA, Kupers R, Dricot L, Ptito M, Behar KL, Rothman DL, Hyder F (2021a) Metabolic
1203 underpinnings of activated and deactivated cortical areas in human brain. *Journal of cerebral*
1204 *blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow*
1205 *and Metabolism*:271678X21989186-271678X21989186.

1206 Koush Y, de Graaf RA, Kupers R, Dricot L, Ptito M, Behar KL, Rothman DL, Hyder F (2021b) Metabolic
1207 underpinnings of activated and deactivated cortical areas in human brain. *J Cereb Blood Flow*
1208 *Metab* 41:986–1000.

1209 Krüger G, Kleinschmidt A, Frahm J (1998) Stimulus dependence of oxygenation-sensitive MRI responses to
1210 sustained visual activation. *NMR Biomed* 11:75–79.

1211 Kühn S, Schubert F, Mekle R, Wenger E, Ittermann B, Lindenberger U, Gallinat J (2016) Neurotransmitter
1212 changes during interference task in anterior cingulate cortex: evidence from fMRI-guided
1213 functional MRS at 3 T. *Brain structure & function* 221:2541–2551.

1214 Kurcyus K, Annac E, Hanning NM, Harris AD, Oeltzschner G, Edden R, Riedl V (2018) Opposite Dynamics of
1215 GABA and Glutamate Levels in the Occipital Cortex during Visual Processing. *The Journal of*
1216 *neuroscience : the official journal of the Society for Neuroscience* 38:9967–9976.

1217 Kuwabara T, Watanabe H, Tsuji S, Yuasa T (1995) Lactate rise in the basal ganglia accompanying finger
1218 movements: a localized¹H-MRS study. *Brain Research* 670:326–328.

1219 Lajeunesse MJ (2016) Facilitating systematic reviews, data extraction and meta-analysis with the
1220 metagear package for r. *Methods in Ecology and Evolution* 7:323–330.

1221 Lally N, Mullins PG, Roberts MV, Price D, Gruber T, Haenschel C (2014) Glutamatergic correlates of
1222 gamma-band oscillatory activity during cognition: a concurrent ER-MRS and EEG study.
1223 *NeuroImage* 85 Pt 2:823–833.

1224 Li C-T, Yang K-C, Lin W-C (2019) Glutamatergic Dysfunction and Glutamatergic Compounds for Major
1225 Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies. *Frontiers in Psychiatry* 9
1226 Available at: <https://www.frontiersin.org/articles/10.3389/fpsyg.2018.00767> [Accessed July 20,
1227 2022].

1228 Ligneul C, Fernandes FF, Shemesh N (2021) High temporal resolution functional magnetic resonance
1229 spectroscopy in the mouse upon visual stimulation. *NeuroImage* 234:117973.

1230 Lin A et al. (2021) Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy
1231 (MRSinMRS): Experts' consensus recommendations. *NMR Biomed* 34:e4484.

1232 Lin L, Chu H (2018) Quantifying Publication Bias in Meta-Analysis. *Biometrics* 74:785–794.

1233 Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG (2012) Investigating the metabolic changes due to
1234 visual stimulation using functional proton magnetic resonance spectroscopy at 7T. *Journal of*

1235 cerebral blood flow and metabolism : official journal of the International Society of Cerebral
1236 Blood Flow and Metabolism 32:1484–1495.

1237 Lynn J, Woodcock EA, Anand C, Khatib D, Stanley JA (2018a) Differences in steady-state glutamate levels
1238 and variability between “non-task-active” conditions: Evidence from ^1H fMRS of the prefrontal
1239 cortex. *NeuroImage* 172:554–561.

1240 Lynn J, Woodcock EA, Anand C, Khatib D, Stanley JA (2018b) Differences in steady-state glutamate levels
1241 and variability between ‘non-task-active’ conditions: Evidence from ^1H fMRS of the prefrontal
1242 cortex. *NeuroImage* 172:554–561.

1243 Ma L-L, Wang Y-Y, Yang Z-H, Huang D, Weng H, Zeng X-T (2020) Methodological quality (risk of bias)
1244 assessment tools for primary and secondary medical studies: what are they and which is better?
1245 *Military Medical Research* 7:7.

1246 Maddock RJ, Casazza GA, Buonocore MH, Tanase C (2011) Vigorous exercise increases brain lactate and
1247 Glx (glutamate+glutamine): a dynamic ^1H -MRS study. *NeuroImage* 57:1324–1330.

1248 Magalhães R, Novais A, Barrière DA, Marques P, Marques F, Sousa JC, Cerqueira JJ, Cachia A, Jay TM,
1249 Bottlaender M, Sousa N, Mériaux S, Boumezbeur F (2019) A Resting-State Functional MR Imaging
1250 and Spectroscopy Study of the Dorsal Hippocampus in the Chronic Unpredictable Stress Rat
1251 Model. *J Neurosci* 39:3640–3650.

1252 Magistretti PJ, Allaman I (2015) A Cellular Perspective on Brain Energy Metabolism and Functional
1253 Imaging. *Neuron* 86:883–901.

1254 Mangia S, Giove F, DiNuzzo M (2012) Metabolic Pathways and Activity-Dependent Modulation of
1255 Glutamate Concentration in the Human Brain. *Neurochem Res* 37:2554–2561.

1256 Mangia S, Giove F, Tkáč I, Logothetis NK, Henry P-G, Olman CA, Maraviglia B, Di Salle F, Uğurbil K (2009)
1257 Metabolic and Hemodynamic Events after Changes in Neuronal Activity: Current Hypotheses,
1258 Theoretical Predictions and *in vivo* NMR Experimental Findings. *J Cereb Blood Flow Metab*
1259 29:441–463.

1260 Mangia S, Tkáč I, Gruetter R, Van de Moortele P-F, Maraviglia B, Uğurbil K (2007) Sustained neuronal
1261 activation raises oxidative metabolism to a new steady-state level: evidence from ^1H NMR
1262 spectroscopy in the human visual cortex. *Journal of cerebral blood flow and metabolism : official*
1263 *journal of the International Society of Cerebral Blood Flow and Metabolism* 27:1055–1063.

1264 Marenco S, Savostyanova AA, van der Veen JW, Geramita M, Stern A, Barnett AS, Kolachana B, Radulescu
1265 E, Zhang F, Callicott JH, Straub RE, Shen J, Weinberger DR (2010) Genetic Modulation of GABA
1266 Levels in the Anterior Cingulate Cortex by GAD1 and COMT. *Neuropsychopharmacol* 35:1708–
1267 1717.

1268 Marjańska M, Deelchand DK, Kreis R, Team the 2016 IMSGFC (2022) Results and interpretation of a
1269 fitting challenge for MR spectroscopy set up by the MRS study group of ISMRM. *Magnetic*
1270 *Resonance in Medicine* 87:11–32.

1271 Martínez-Maestro M, Labadie C, Möller HE (2019) Dynamic metabolic changes in human visual cortex in
1272 regions with positive and negative blood oxygenation level-dependent response. *Journal of*
1273 *cerebral blood flow and metabolism : official journal of the International Society of Cerebral*
1274 *Blood Flow and Metabolism* 39:2295–2307.

1275 Mekle R, Kühn S, Pfeiffer H, Aydin S, Schubert F, Ittermann B (2017) Detection of metabolite changes in
1276 response to a varying visual stimulation paradigm using short-TE (1) H MRS at 7 T. *NMR in*
1277 *biomedicine* 30.

1278 Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R (1998) Simultaneous in vivo spectral editing and
1279 water suppression. *NMR Biomed* 11:266–272.

1280 Michels L, Martin E, Klaver P, Edden R, Zelaya F, Lythgoe DJ, Lüchinger R, Brandeis D, O’Gorman RL (2012)
1281 Frontal GABA Levels Change during Working Memory. *PLOS ONE* 7:e31933.

1282 Mikkelsen M, Loo RS, Puts NAJ, Edden RAE, Harris AD (2018) Designing GABA-Edited Magnetic Resonance
1283 Spectroscopy Studies: Considerations of Scan Duration, Signal-To-Noise Ratio and Sample Size. *J*
1284 *Neurosci Methods* 303:86–94.

1285 Minati L, Aquino D, Bruzzone MG, Erbetta A (2010) Quantitation of normal metabolite concentrations in
1286 six brain regions by in-vivo 1H-MR spectroscopy. *J Med Phys* 35:154–163.

1287 Mullins PG (2018) Towards a theory of functional magnetic resonance spectroscopy (fMRS): A meta-
1288 analysis and discussion of using MRS to measure changes in neurotransmitters in real time. *Scand*
1289 *J Psychol* 59:91–103.

1290 Mullins PG, McGonigle DJ, O’Gorman RL, Puts NAJ, Vidyasagar R, Evans CJ, Cardiff Symposium on MRS of
1291 GABA, Edden RAE (2014) Current practice in the use of MEGA-PRESS spectroscopy for the
1292 detection of GABA. *Neuroimage* 86:43–52.

1293 Mullins PG, Rowland LM, Jung RE, Sibbitt WL (2005) A novel technique to study the brain’s response to
1294 pain: Proton magnetic resonance spectroscopy. *NeuroImage* 26:642–646.

1295 Murphy KR, Aguinis H (2019) HARKing: How Badly Can Cherry-Picking and Question Trolling Produce Bias
1296 in Published Results? *Journal of Business and Psychology* 34:1–17.

1297 Muthukumaraswamy SD, Evans CJ, Edden RAE, Wise RG, Singh KD (2012) Individual variability in the
1298 shape and amplitude of the BOLD-HRF correlates with endogenous GABAergic inhibition. *Human*
1299 *Brain Mapping* 33:455–465.

1300 Nakagawa S, Lagisz M, Jennions MD, Koricheva J, Noble DW, Parker TH, Sánchez-Tójar A, Yang Y, O’Dea RE
1301 (2021) Methods for testing publication bias in ecological and evolutionary meta-analyses.
1302 *Methods in Ecology and Evolution*.

1303 Nakahara T et al. (2022) Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum
1304 disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. *Mol Psychiatry*
1305 27:744–757.

1306 Narayanan NS, Laubach M (2017) Inhibitory Control: Mapping Medial Frontal Cortex. *Current Biology*
1307 27:R148–R150.

1308 Near J, Simpson R, Cowen P, Jezzard P (2011) Efficient γ -aminobutyric acid editing at 3T without
1309 macromolecule contamination: MEGA-SPECIAL. *NMR Biomed* 24:1277–1285.

1310 Öz G, Tkáč I (2011) Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for
1311 neurochemical profiling at 4 T: Validation in the cerebellum and brainstem. *Magnetic Resonance*
1312 in Medicine 65:901–910.

1313 Page MJ et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
1314 *BMJ* 372:n71.

1315 Paredes RG, Agmo A (1992) GABA and behavior: the role of receptor subtypes. *Neurosci Biobehav Rev*
1316 16:145–170.

1317 Peek AL, Rebbeck T, Puts NA, Watson J, Aguila M-ER, Leaver AM (2020) Brain GABA and glutamate levels
1318 across pain conditions: A systematic literature review and meta-analysis of 1H-MRS studies using
1319 the MRS-Q quality assessment tool. *Neuroimage* 210:116532.

1320 Porges EC, Woods AJ, Lamb DG, Williamson JB, Cohen RA, Edden RAE, Harris AD (2017) Impact of tissue
1321 correction strategy on GABA-edited MRS findings. *NeuroImage* 162:249–256.

1322 Pouwels PJ, Frahm J (1998) Regional metabolite concentrations in human brain as determined by
1323 quantitative localized proton MRS. *Magn Reson Med* 39:53–60.

1324 Prichard JW (1992) Magnetic resonance spectroscopy of the brain. *Clin Chim Acta* 206:115–123.

1325 Pustejovsky JE, Tipton E (2021) Meta-analysis with Robust Variance Estimation: Expanding the Range of
1326 Working Models. *Prev Sci*.

1327 Puts NAJ, Edden RAE (2012) In vivo magnetic resonance spectroscopy of GABA: A methodological review.
1328 *Prog Nucl Magn Reson Spectrosc* 60:29–41.

1329 Puts NAJ, Edden RAE, Evans CJ, McGlone F, McGonigle DJ (2011) Regionally Specific Human GABA
1330 Concentration Correlates with Tactile Discrimination Thresholds. *J Neurosci* 31:16556–16560.

1331 Rae C, Nasrallah FA, Griffin JL, Balcar VJ (2009) Now I know my ABC. A systems neurochemistry and
1332 functional metabolomic approach to understanding the GABAergic system. *J Neurochem* 109
1333 Suppl 1:109–116.

1334 Rae CD (2014) A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain
1335 1H Magnetic Resonance Spectra. *Neurochem Res* 39:1–36.

1336 Rideaux R (2020) Temporal Dynamics of GABA and Glx in the Visual Cortex. *eNeuro* 7 Available at:
1337 <https://www.eneuro.org/content/7/4/ENEURO.0082-20.2020> [Accessed January 7, 2022].

1338 Rideaux R (2021) No balance between glutamate+glutamine and GABA+ in visual or motor cortices of the
1339 human brain: A magnetic resonance spectroscopy study. *NeuroImage* 237:118191.

1340 Rosenthal R (1979) The file drawer problem and tolerance for null results. *Psychological Bulletin* 86:638–
1341 641.

1342 Rosenthal R (1986) *Meta-Analytic Procedures for Social Science Research* Sage Publications: Beverly Hills,
1343 1984, 148 pp. *Educational Researcher* 15:18–20.

1344 Rothman DL, Behar KL, Hyder F, Shulman RG (2003) In vivo NMR studies of the glutamate
1345 neurotransmitter flux and neuroenergetics: implications for brain function. *Annu Rev Physiol*
1346 65:401–427.

1347 Ruppert D, Wand MP (1994) Multivariate Locally Weighted Least Squares Regression. *The Annals of*
1348 *Statistics* 22:1346–1370.

1349 Sanaei Nezhad F, Anton A, Michou E, Jung J, Parkes LM, Williams SR (2018) Quantification of GABA,
1350 glutamate and glutamine in a single measurement at 3 T using GABA-edited MEGA-PRESS. *NMR*
1351 in *Biomedicine* 31:e3847.

1352 Schaller B, Mekle R, Xin L, Kunz N, Gruetter R (2013) Net increase of lactate and glutamate concentration
1353 in activated human visual cortex detected with magnetic resonance spectroscopy at 7 tesla.
1354 *Journal of neuroscience research* 91:1076–1083.

1355 Schaller B, Xin L, O'Brien K, Magill AW, Gruetter R (2014) Are glutamate and lactate increases ubiquitous
1356 to physiological activation? A (1)H functional MR spectroscopy study during motor activation in
1357 human brain at 7Tesla. *NeuroImage* 93 Pt 1:138–145.

1358 Schür RR, Draisma LWR, Wijnen JP, Boks MP, Koevoets MGJC, Joëls M, Klomp DW, Kahn RS, Vinkers CH
1359 (2016) Brain GABA levels across psychiatric disorders: A systematic literature review and meta-
1360 analysis of 1H-MRS studies. *Human Brain Mapping* 37:3337–3352.

1361 Shi L, Lin L (2019) The trim-and-fill method for publication bias: practical guidelines and recommendations
1362 based on a large database of meta-analyses. *Medicine* 98:e15987.

1363 Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling of
1364 brain glucose metabolism and glutamatergic neuronal activity. *PNAS* 95:316–321.

1365 Siniatchkin M, Sendacki M, Moeller F, Wolff S, Jansen O, Siebner H, Stephani U (2012) Abnormal changes
1366 of synaptic excitability in migraine with aura. *Cerebral cortex (New York, NY : 1991)* 22:2207–
1367 2216.

1368 Stagg CJ, Bachtiar V, Johansen-Berg H (2011) The Role of GABA in Human Motor Learning. *Curr Biol*
1369 21:480–484.

1370 Stagg CJ, Best JG, Stephenson MC, O'Shea J, Wylezinska M, Kincses ZT, Morris PG, Matthews PM,
1371 Johansen-Berg H (2009) Polarity-Sensitive Modulation of Cortical Neurotransmitters by
1372 Transcranial Stimulation. *J Neurosci* 29:5202–5206.

1373 Stanley JA, Burgess A, Khatib D, Ramaseshan K, Arshad M, Wu H, Diwadkar VA (2017) Functional dynamics
1374 of hippocampal glutamate during associative learning assessed with in vivo (1)H functional
1375 magnetic resonance spectroscopy. *NeuroImage* 153:189–197.

1376 Stanley JA, Raz N (2018) Functional Magnetic Resonance Spectroscopy: The “New” MRS for Cognitive
1377 Neuroscience and Psychiatry Research. *Frontiers in Psychiatry* 9:76.

1378 Steel A, Mikkelsen M, Edden RA, Robertson CE (2020) Regional balance between glutamate+ glutamine
1379 and GABA+ in the resting human brain. *Neuroimage* 220:117112.

1380 Steen RG, Hamer RM, Lieberman JA (2005) Measurement of brain metabolites by ^1H magnetic resonance
1381 spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.
1382 *Neuropsychopharmacology* 30:1949–1962.

1383 Sterne JAC, Egger M (2001) Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis.
1384 *Journal of Clinical Epidemiology* 54:1046–1055.

1385 Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of Meta-Essentials: A
1386 free and simple tool for meta-analysis. *Research Synthesis Methods* 8:537–553.

1387 Takado Y, Takuwa H, Sampei K, Urushihata T, Takahashi M, Shimojo M, Uchida S, Nitta N, Shibata S,
1388 Nagashima K, Ochi Y, Ono M, Maeda J, Tomita Y, Sahara N, Near J, Aoki I, Shibata K, Higuchi M
1389 (2021) MRS-measured glutamate versus GABA reflects excitatory versus inhibitory neural
1390 activities in awake mice. *J Cereb Blood Flow Metab*:0271678X211045449.

1391 Tang X, Jaenisch R, Sur M (2021) The role of GABAergic signalling in neurodevelopmental disorders. *Nat*
1392 *Rev Neurosci* 22:290–307.

1393 Taylor R, Neufeld RWJ, Schaefer B, Densmore M, Rajakumar N, Osuch EA, Williamson PC, Théberge J
1394 (2015a) Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major
1395 depressive disorder: anterior cingulate activity during a color-word Stroop task. *NPJ schizophrenia*
1396 1:15028–15028.

1397 Taylor R, Schaefer B, Densmore M, Neufeld RWJ, Rajakumar N, Williamson PC, Théberge J (2015b)
1398 Increased glutamate levels observed upon functional activation in the anterior cingulate cortex
1399 using the Stroop Task and functional spectroscopy. *Neuroreport* 26:107–112.

1400 Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednařík P, Eberly LE, Öz G (2016) Test-retest
1401 reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and
1402 7T. *Magn Reson Med* 76:1083–1091.

1403 Terrin N, Schmid CH, Lau J, Olkin I (2003) Adjusting for publication bias in the presence of heterogeneity.
1404 *Stat Med* 22:2113–2126.

1405 Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MD, Horsley T, Weeks L
1406 (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of*
1407 *internal medicine* 169:467–473.

1408 Valtcheva S, Venance L (2019) Control of Long-Term Plasticity by Glutamate Transporters. *Frontiers in*
1409 *Synaptic Neuroscience* 11:10.

1410 Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. *Journal of statistical*
1411 *software* 36:1–48.

1412 Vijayakumari AA, Menon RN, Thomas B, Arun TM, Nandini M, Kesavadas C (2020) Glutamatergic response
1413 to a low load working memory paradigm in the left dorsolateral prefrontal cortex in patients with
1414 mild cognitive impairment: a functional magnetic resonance spectroscopy study. *Brain imaging*
1415 and behavior

1416 Vijayakumari AA, Thomas B, Menon RN, Kesavadas C (2018) Association between glutamate/glutamine
1417 and blood oxygen level dependent signal in the left dorsolateral prefrontal region during verbal
1418 working memory. *Neuroreport* 29:478–482.

1419 Volovyk O, Tal A (2020) Increased Glutamate concentrations during prolonged motor activation as
1420 measured using functional Magnetic Resonance Spectroscopy at 3T. *NeuroImage* 223:117338–
1421 117338.

1422 Wilson M et al. (2019) Methodological consensus on clinical proton MRS of the brain: Review and
1423 recommendations. *Magnetic Resonance in Medicine* 82:527–550.

1424 Woodcock EA, Anand C, Khatib D, Diwadkar VA, Stanley JA (2018) Working Memory Modulates Glutamate
1425 Levels in the Dorsolateral Prefrontal Cortex during (1)H fMRS. *Frontiers in psychiatry* 9:66–66.

1426 Woodcock EA, Greenwald MK, Khatib D, Diwadkar VA, Stanley JA (2019) Pharmacological stress impairs
1427 working memory performance and attenuates dorsolateral prefrontal cortex glutamate
1428 modulation. *NeuroImage* 186:437–445.

1429 Yashiro K, Corlew R, Philpot BD (2005) Visual Deprivation Modifies Both Presynaptic Glutamate Release
1430 and the Composition of Perisynaptic/Extrasynaptic NMDA Receptors in Adult Visual Cortex. *J*
1431 *Neurosci* 25:11684–11692.

1432 Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz
1433 JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K (2011)
1434 Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature*
1435 477:171–178.

1436 Zhang X, Liang M, Qin W, Wan B, Yu C, Ming D (2020) Gender Differences Are Encoded Differently in the
1437 Structure and Function of the Human Brain Revealed by Multimodal MRI. *Frontiers in Human*
1438 *Neuroscience* 14 Available at: <https://www.frontiersin.org/article/10.3389/fnhum.2020.00244>
1439 [Accessed January 25, 2022].

1440 Zhu X-H, Chen W (2001) Observed BOLD effects on cerebral metabolite resonances in human visual
1441 cortex during visual stimulation: A functional 1H MRS study at 4 T. *Magnetic Resonance in*
1442 *Medicine* 46:841–847.

1443 Zöllner HJ, Považan M, Hui SCN, Tapper S, Edden RAE, Oeltzschn G (2021) Comparison of different
1444 linear-combination modeling algorithms for short-TE proton spectra. *NMR in Biomedicine*
1445 34:e4482.

1446 Zöllner HJ, Tapper S, Hui SCN, Barker PB, Edden RAE, Oeltzschn G (2022) Comparison of linear
1447 combination modeling strategies for edited magnetic resonance spectroscopy at 3 T. *NMR*
1448 *Biomed* 35:e4618.

1449

1450

1451